Topics

SGLT2 Inhibitors and Cognitive Impairment

Diabetes Metabolic Diseases Neurodegeneration Chronic Inflammation

Sodium-glucose cotransporter-2 inhibitors reduce renal glucose reabsorption and were developed for type 2 diabetes, with established cardiorenal uses. Their possible relationship with cognitive impairment emerged from the vascular and metabolic links among diabetes, kidney disease, heart failure, and dementia, followed by animal studies of brain inflammation, oxidative stress, insulin signaling, and amyloid pathology. Proposed cognitive benefit could arise indirectly through improved glycemia, blood pressure, vascular function, renal status, or heart failure, or through direct changes in neural metabolism and inflammatory signaling. Interest is substantial, but SGLT2 inhibitors are not established treatments for cognitive impairment or Alzheimer disease[1].

Mechanistic models include reduced glucotoxicity, improved insulin sensitivity, ketone availability, lower oxidative and inflammatory stress, preserved blood-brain barrier function, and altered microglial activity. These pathways are biologically plausible but difficult to separate from systemic cardiorenal effects, and brain exposure differs among agents. Observational evidence is encouraging: a Korean population-based cohort of 110,885 matched pairs aged 40-69 with type 2 diabetes found lower incident dementia after SGLT2-inhibitor initiation than after DPP-4-inhibitor initiation. The authors explicitly noted residual confounding and informative censoring and called for randomized trials. Association cannot determine whether the drug prevents dementia, the comparator changes risk, or treated populations differ in unmeasured ways[1][2].

Randomized evidence remains mixed and exploratory. A meta-analysis of cardiovascular-outcome and glucose-lowering trials found no statistically significant reduction in dementia or cognitive impairment for SGLT2 inhibitors, although cognition was not the primary outcome in most contributing trials. In a small 12-week randomized study of probable early Alzheimer disease, dapagliflozin did not change the primary cerebral N-acetylaspartate outcome; brain glutathione and one executive test changed, but other cognitive tests did not. A separate four-week phase 2A/B factorial trial in mild cognitive impairment or early Alzheimer disease found empagliflozin was tolerated and changed cerebrospinal-fluid tau, cerebral blood flow, and several inflammatory or neurovascular markers; the study was too short and small to establish durable cognitive efficacy[3][4][5].

Future trials must separate prevention in diabetes from treatment of established neurodegeneration. Prevention studies need long follow-up, adjudicated dementia subtypes, active comparators, renal and cardiovascular covariates, and prespecified cognition. Alzheimer trials need biomarker-confirmed disease, adequate duration, functional endpoints, and evidence of central target engagement. Head-to-head studies should determine whether any cognitive signal reflects glucose lowering, cardiorenal protection, ketone metabolism, vascular change, or a brain-specific effect. Hypoglycemia is uncommon with SGLT2 inhibition alone, but volume depletion, genital infection, ketoacidosis, renal function, frailty, and weight loss require context-specific monitoring. Studies should compare agents rather than assuming a uniform class effect and should test whether benefit depends on diabetes, kidney disease, vascular burden, or baseline insulin resistance. Repeated cognitive testing, digital function measures, imaging, cerebrospinal-fluid markers, and treatment adherence should be analyzed together. Larger, longer, independently replicated multicenter trials across diverse populations and settings remain essential. Trials must be powered for meaningful cognitive and daily-function change rather than isolated biomarker movement. Current evidence supports continued investigation, not prescribing an SGLT2 inhibitor solely for cognitive protection[1][2][3][4][5].

Articles

All
  • All
  • Scientific Reviews
  • EDM
  • Product Guides
  • Blog
Most Recent
  • Most Recent
  • Oldest

Products

All
  • All
  • Inhibitors & Agonists
  • Isotope-Labeled Compounds
  • Fluorescent Dye
  • Peptides
  • Recombinant Proteins
  • Antibodies
  • Screening Libraries
  • Inhibitory Antibodies
  • Reference Standards
  • Induced Disease Models Products
  • GMP Small Molecules
  • Biochemical Assay Reagents
  • Natural Products
Cat. No. Product Name Information Application Publication
HY-13418 Dorsomorphin dihydrochloride
Dorsomorphin (Compound C) dihydrochloride is a potent, selective and ATP-competitive AMPK inhibitor, with a Ki of 109 nM. Dorsomorphin dihydrochloride inhibits BMP pathway by targeting the type I receptors ALK2, ALK3, and ALK6. Dorsomorphin dihydrochloride can reverse autophagy activation and anti-inflammatory effect of Urolithin A (HY-100599).
Organoid   AMPK   TGF-β Receptor   Autophagy  
Colorectal Cancer   Prostate Cancer   Ovarian Cancer   Pain   Digestive System Inflammation   Obesity  
819
HY-13418A Dorsomorphin
Dorsomorphin (BML-275) is a selective and ATP-competitive AMPK inhibitor (Ki=109 nM in the absence of AMP). Dorsomorphin (BML-275) selectively inhibits BMP type I receptors ALK2, ALK3, and ALK6. Dorsomorphin can reverse autophagy activation and anti-inflammatory effect of Urolithin A (HY-100599).
Organoid   AMPK   TGF-β Receptor   Autophagy  
819
HY-15142 Doxorubicin hydrochloride
Doxorubicin hydrochloride (Hydroxydaunorubicin hydrochloride; ADR), a cytotoxic anthracycline antibiotic, is an anti-cancer chemotherapy agent. Doxorubicin hydrochloride is a potent human DNA topoisomerase I and topoisomerase II inhibitor with IC50s of 0.8 μM and 2.67 μM, respectively. Doxorubicin hydrochloride reduces basal phosphorylation of AMPK and its downstream target acetyl-CoA carboxylase. Doxorubicin hydrochloride induces apoptosis and autophagy.

Source: Streptomyces peucetius var. Caesius

Topoisomerase   ADC Payloads   AMPK   Autophagy   Apoptosis   HIV   HBV   Mitophagy   Antibiotic   Bacterial   Fluorescent Dye  
Non-Small Cell Lung Cancer   HER-2 Positive Breast Cancer   Triple-Negative Breast Cancer   Metastatic Breast Cancer  
711
HY-100523 ML385
ML385 is a potent and selective Nrf2 inhibitor with an IC50 of 1.9 μM. ML385 directly binds to the Neh1 domain of NRF2, interferes with the binding of the MAFG-NRF2 protein complex to the antioxidant response element (ARE) DNA sequence, thereby blocking the expression of downstream target genes of NRF2. ML385 can be used in studies related to adult T-cell leukemia, breast cancer, myocardial ischemia/reperfusion injury, non-small cell lung cancer, esophageal squamous cell carcinoma, head and neck squamous cell carcinoma, and lung squamous cell carcinoma.
Keap1-Nrf2   Ferroptosis   Apoptosis   mTOR  
Breast Cancer   Colorectal Cancer   Cardiovascular Disease   Non-Small Cell Lung Cancer   Lung Squamous Cell Carcinoma   Squamous Cell Carcinoma   Esophageal Cancer  
644
HY-12815A MCC950 sodium
MCC950 sodium (CP-456773 sodium; CRID3 sodium salt) is a potent, selective NLRP3 inhibitor with IC50s of 7.5 and 8.1 nM in BMDMs and HMDMs, respectively.
NOD-like Receptor (NLR)  
Depression   Autoimmune Disease  
497
HY-12815 MCC950
MCC950 (CP-456773; CRID3) is a potent and selective NLRP3 inhibitor with IC50s of 7.5 and 8.1 nM in BMDMs and HMDMs, respectively.
NOD-like Receptor (NLR)  
Depression   Autoimmune Disease  
497
HY-100381 Nigericin sodium salt
Nigericin sodium salt is an antibiotic derived from Streptomyces hygroscopicus that act as a K+/H+ ionophore, promoting K+/H+ exchange across mitochondrial membranes. Nigericin sodium salt is a NLRP3 activator. Nigericin sodium salt shows promising anti-cancer activities through decreasing intracellular pH (pHi), and inactivation of Wnt/β-catenin signals. Nigericin sodium salt induces pyroptosis through caspase 1/GSDMD in TNBC.

Source: Streptomyces hygroscopicus

Potassium Channel   NOD-like Receptor (NLR)   Bacterial   Antibiotic   Pyroptosis   Wnt   β-catenin  
Breast Cancer   Colorectal Cancer   Prostate Cancer   Gastric Cancer   Liver Cancer   Ovarian Cancer   Bacterial Infection   Depression   Hypertension   Lung Fibrosis   Rheumatoid Arthritis  
258
HY-127019 Nigericin
Nigericin is an antibiotic derived from Streptomyces hygroscopicus that act as a K+/H+ ionophore, promoting K+/H+ exchange across mitochondrial membranes. Nigericin is a NLRP3 activator. Nigericin shows promising anti-cancer activities through decreasing intracellular pH (pHi), and inactivation of Wnt/β-catenin signals. Nigericin induces pyroptosis through caspase 1/GSDMD in TNBC.
Potassium Channel   NOD-like Receptor (NLR)   Bacterial   Antibiotic   Pyroptosis   Wnt   β-catenin  
Breast Cancer   Colorectal Cancer   Prostate Cancer   Gastric Cancer   Liver Cancer   Ovarian Cancer   Bacterial Infection   Depression   Hypertension   Lung Fibrosis   Rheumatoid Arthritis  
258
HY-13417 AICAR
AICAR (Acadesine) is an adenosine analog and a AMPK activator. AICAR is also an autophagy, YAP and mitophagy inhibitor. AICAR regulates the glucose and lipid metabolism, and inhibits proinflammatory cytokines and iNOS production. AICAR inhibits autophagy through a mechanism independent of AMPK activity.
AMPK   Autophagy   YAP   Mitophagy   Endogenous Metabolite  
Cancer  
231
HY-17471A Metformin hydrochloride
Metformin (1,1-Dimethylbiguanide) hydrochloride inhibits the mitochondrial respiratory chain in the liver, leading to AMPK activation and enhancing insulin sensitivity, and can be used in the study of type 2 diabetes. Metformin hydrochloride exerts central glucose-lowering effects by inhibiting Ras-related protein 1 (Rap1) in SF1 hypothalamic neurons. Metformin hydrochloride also inhibits liver oxidative stress, nitrosative stress, inflammation, and apoptosis caused by liver ischemia/reperfusion injury. In addition, Metformin hydrochloride regulates the expression of autophagy-related proteins by activating AMPK and inhibiting the mTOR signaling pathway, thereby inducing tumor cell autophagy and inhibiting the growth of renal cell carcinoma in vitro and in vivo.
AMPK   Autophagy   Mitophagy   Apoptosis   mTOR  
Colorectal Cancer   Prostate Cancer   Gastric Cancer   Liver Cancer   Leukemia/Lymphoma/Myeloma   Pancreatic Cancer   Ovarian Cancer   Viral Infection   Digestive System Inflammation   Cardiovascular Disease   Glucose Metabolism   Non-Small Cell Lung Cancer   Lung Adenocarcinoma   Large Cell Lung Carcinoma   HER-2 Positive Breast Cancer   Triple-Negative Breast Cancer   Metastatic Breast Cancer   SARS-CoV-2 Infection   Parkinson's Disease   Chronic Pain   Obesity  
212
HY-B0627 Metformin
Metformin (1,1-Dimethylbiguanide) inhibits the mitochondrial respiratory chain in the liver, leading to AMPK activation and enhancing insulin sensitivity, and can be used in the study of type 2 diabetes. Metformin exerts central glucose-lowering effects by inhibiting Ras-related protein 1 (Rap1) in SF1 hypothalamic neurons. Metformin also inhibits liver oxidative stress, nitrosative stress, inflammation, and apoptosis caused by liver ischemia/reperfusion injury. In addition, Metformin regulates the expression of autophagy-related proteins by activating AMPK and inhibiting the mTOR signaling pathway, thereby inducing tumor cell autophagy and inhibiting the growth of renal cell carcinoma in vitro and in vivo.
AMPK   Autophagy   Mitophagy   Apoptosis   mTOR  
Colorectal Cancer   Prostate Cancer   Gastric Cancer   Liver Cancer   Leukemia/Lymphoma/Myeloma   Pancreatic Cancer   Ovarian Cancer   Viral Infection   Pain   Digestive System Inflammation   Cardiovascular Disease   Glucose Metabolism   Non-Small Cell Lung Cancer   Lung Adenocarcinoma   Large Cell Lung Carcinoma   HER-2 Positive Breast Cancer   Triple-Negative Breast Cancer   Metastatic Breast Cancer   Parkinson's Disease   Obesity   Lung Fibrosis  
212
HY-L022 FDA-Approved Drug Library
New drug development is a time-consuming and high-cost process. Drug repurposing (also called drug repositioning, reprofiling or re‑tasking) offers various advantages over developing an entirely new drug for a given indication. First, the risk of failure is lower. Second, the time frame for drug development can be reduced. Third, less investment is needed. Approved drugs have identified bioactivities, good pharmacokinetic characteristics and safety which are suitable for drug repurposing. MCE owns a unique collection of 3,236 approved compounds which have been completed extensive preclinical and clinical studies and have well-characterized bioactivities, safety and bioavailability properties. MCE FDA-Approved Drug Library is a good tool for drug repurposing which could dramatically accelerate drug development.

Drug Repurposing Series

195
HY-112879 Mito-TEMPO
Mito-TEMPO is a mitochondria-targeted antioxidant. Mito-TEMPO induces mitophagy by activating the PINK1/Parkin pathway, inhibits NLRP3 inflammasome activation, restores mitochondrial membrane potential, and improves renal function and podocyte injury. Mito-TEMPO regulates Ca2+ homeostasis, inhibits Bnip3 overexpression, shortens action potential duration, and exerts antiarrhythmic effects. Mito-TEMPO reverses premature senescence, reduces trabecular bone loss, and decreases cell apoptosis. Mito-TEMPO can be used in studies of chronic kidney disease, age-related cardiac dysfunction, postmenopausal osteoporosis, and ischemic stroke.
Calcium Channel   Apoptosis   Mitochondrial Metabolism   NOD-like Receptor (NLR)   PINK1/Parkin   Autophagy  
Ischemic Stroke   Osteoporosis   Chronic Kidney Disease  
186
HY-B2176 ATP
ATP (Adenosine 5'-triphosphate) is a central component of energy storage and metabolism in vivo. ATP provides the metabolic energy to drive metabolic pumps and serves as a coenzyme in cells. ATP is an important endogenous signaling molecule in immunity and inflammation. ATP can activate the NLRP3 inflammasome and induce IL-1β and chemokines secretion. ATP has anti-bacterial infection effects and can protect mice against bacterial infection in mice.

Source: widespread

Endogenous Metabolite   NOD-like Receptor (NLR)   Interleukin Related   Bacterial  
Infection   Inflammation or Immune System Disease   Metabolic or Endocrine Disease  
178
HY-16561 Resveratrol
Resveratrol (trans-Resveratrol; SRT501) is a CNS-penetrant natural polyphenolic phytoalexin that possesses anti-oxidant, anti-inflammatory, cardioprotective, and anti-cancer properties. Resveratrol (SRT 501) has a wide spectrum of targets including mTOR, JAK, β-amyloid, Adenylyl cyclase, IKKβ, DNA polymerase. Resveratrol also is a specific SIRT1 activator. Resveratrol is a potent pregnane X receptor (PXR) inhibitor. Resveratrol is an Nrf2 activator, ameliorates aging-related progressive renal injury in mice model. Resveratrol increases production of NO in endothelial cells.
DNA/RNA Synthesis   IKK   Autophagy   Mitophagy   Sirtuin   Apoptosis   Bacterial   Fungal   Antibiotic   Keap1-Nrf2  
Neurological, Eye or Ear Disease   Prostate Cancer   Liver Cancer   Bacterial Infection   Fungal Infection   Digestive System Inflammation   Glucose Metabolism   SARS-CoV-2 Infection   Obesity   Lung Fibrosis  
174
HY-13027 DAPT
DAPT (GSI-IX) is a potent and orally active γ-secretase inhibitor with IC50s of 115 nM and 200 nM for total amyloid-β (Aβ) and Aβ42, respectively. DAPT inhibits the activation of Notch 1 signaling and induces cell differentiation. DAPT also induces autophagy and apoptosis. DAPT has neuroprotection activity and has the potential for autoimmune and lymphoproliferative diseases, degenerative disease and cancers treatment.
Organoid   γ-secretase   Amyloid-β   Autophagy   Notch   Apoptosis  
Breast Cancer   Colorectal Cancer   Liver Cancer   Pancreatic Cancer   Digestive System Inflammation   Alzheimer's Disease   Rheumatoid Arthritis  
172
HY-100573 Necrosulfonamide
Necrosulfonamide is a MLKL and Gasdermin D (GSDMD) inhibitor, capable of separately inhibiting necroptosis and pyroptosis of cells. Necrosulfonamide does not affect the activation of upstream signals, but specifically inhibits the downstream executor oligomerization step. Necrosulfonamide reduces the expression of the key kinases NLRP3 and caspase-1 involved in necroptosis and pyroptosis, activate the Nrf2 pathway and the downstream antioxidant enzymes, and also downregulates a variety of inflammatory factors. Necrosulfonamide plays significant roles in various diseases such as neurodegenerative diseases (such as Parkinson’s disease), tissue damage and ischemia-reperfusion injury, inflammatory bowel disease, osteoarthritis and fracture repair, and hair loss by regulating two important programmed necrosis pathways.
Mixed Lineage Kinase   Necroptosis   Pyroptosis   Caspase   NOD-like Receptor (NLR)   Keap1-Nrf2   TNF Receptor   Interleukin Related   NO Synthase   Heme Oxygenase (HO)  
Digestive System Disease   Prostate Cancer   Leukemia/Lymphoma/Myeloma   Depression   Digestive System Inflammation   Cardiovascular Disease   Parkinson's Disease   Obesity   Lung Fibrosis   Rheumatoid Arthritis  
147
HY-N0005 Curcumin
Curcumin (Diferuloylmethane), a natural phenolic compound, is a p300/CREB-binding protein-specific inhibitor of acetyltransferase, represses the acetylation of histone/nonhistone proteins and histone acetyltransferase-dependent chromatin transcription. Curcumin is a photosensitizer against microorganisms. Curcumin shows inhibitory effects on NF-κB and MAPKs, and has diverse pharmacologic effects including anti-inflammatory, antioxidant, antiproliferative and antiangiogenic activities. Curcumin induces stabilization of Nrf2 protein through Keap1 cysteine modification.
Histone Acetyltransferase   Epigenetic Reader Domain   Keap1-Nrf2   Autophagy   Mitophagy   Influenza Virus   Ferroptosis   Apoptosis  
Prostate Cancer   Leukemia/Lymphoma/Myeloma   Pancreatic Cancer   Viral Infection   Pain   Digestive System Inflammation   Glucose Metabolism   Metastatic Breast Cancer   SARS-CoV-2 Infection   Obesity   Lung Fibrosis  
138
HY-100489 TBHQ
TBHQ (tert-Butylhydroquinone) is a widely used Nrf2 activator, protects against Doxorubicin (DOX)-induced cardiotoxicity through activation of Nrf2. TBHQ (tert-Butylhydroquinone) is also an ERK activator; rescues Dehydrocorydaline (DHC)-induced cell proliferation inhibitionin melanoma.
Environmental Pollutants   Autophagy   ERK   Ferroptosis   Keap1-Nrf2   Apoptosis  
Cancer   Digestive System Disease   Depression   Pain   Digestive System Inflammation   Obesity   Lung Fibrosis  
131
HY-L035 Drug Repurposing Compound Library
New drug development is a time-consuming and high-cost process. Drug repurposing (also called drug repositioning, reprofiling or re‑tasking) offers various advantages over developing an entirely new drug for a given indication. First, the risk of failure is lower. Second, the time frame for drug development can be reduced. Third, less investment is needed. Approved and clinical drugs, especially after phase I drugs, have identified bioactivities, good pharmacokinetic characteristics and safety which are suitable for drug repurposing. MCE Drug Repurposing Compound Library contains 5,148 approved drugs and passed phase Ⅰclinical drugs, which have been completed extensive preclinical and clinical studies and have well-characterized bioactivities, safety and bioavailability properties.

Drug Repurposing Series

109
HY-P0035A Insulin solution (human)
Insulin solution (human) is a polypeptide hormone that regulates the level of glucose. Insulin solution (human) can be used for the diabetes mellitus.
Insulin Receptor  
Metabolic or Endocrine Disease  
105
HY-P0035 Insulin (human)
Insulin (human) is a polypeptide hormone that regulates the level of glucose. Insulin (human) can be used for the diabetes mellitus.
Insulin Receptor  
Metabolic or Endocrine Disease  
105
HY-P1061A Colivelin TFA
Colivelin TFA is a brain penetrant neuroprotective peptide and a potent activator of STAT3, suppresses neuronal death by activating STAT3 in vitro. Colivelin TFA exhibits long-term beneficial effects against neurotoxicity, Aβ deposition, neuronal apoptosis, and synaptic plasticity deficits in neurodegenerative disease. Colivelin TFA has the potential for the treatment of alzheimer's disease and ischemic brain injury.
STAT   Amyloid-β   Apoptosis  
Neurological, Eye or Ear Disease  
102
HY-P1061 Colivelin
Colivelin is a brain penetrant neuroprotective peptide and a potent activator of STAT3, suppresses neuronal death by activating STAT3 in vitro. Colivelin exhibits long-term beneficial effects against neurotoxicity, Aβ deposition, neuronal apoptosis, and synaptic plasticity deficits in neurodegenerative disease. Colivelin has the potential for the treatment of alzheimer's disease and ischemic brain injury
STAT   Amyloid-β  
Neurological, Eye or Ear Disease  
102
HY-112675 4-Octyl itaconate
4-Octyl Itaconate is a cell-permeable Itaconate derivative. Itaconate is an anti-inflammatory metabolite that activates Nrf2 via alkylation of KEAP1.
Keap1-Nrf2  
Inflammation or Immune System Disease   Obesity   Lung Fibrosis  
98
HY-L066 FDA Approved & Pharmacopeial Drug Library
New drug development is a time-consuming and high-cost process. Drug repurposing (also called drug repositioning, reprofiling or retasking) offers various advantages over developing an entirely new drug for a given indication. First, the risk of failure is lower. Second, the time frame for drug development can be reduced. Third, less investment is needed. Approved drugs and pharmacopoeia collected compounds have identified bioactivities, good pharmacokinetic characteristics and safety which are suitable for drug repurposing. MCE owns a unique collection of 3,750 compounds from approved institutions such as FDA, EMA, NMPA, PMDA, etc. or pharmacopoeia such as USP, BP, JP, etc. These compounds have well-characterized bioactivities, safety and bioavailability properties. MCE FDA Approved & Pharmacopeial Drug Library is a good tool for drug repurposing which could dramatically accelerate drug development.

Drug Repurposing Series

98
HY-L068 Flavonoids Library
Flavonoids are an important class of natural products; particularly, they belong to a class of plant secondary metabolites having a polyphenolic structure, widely found in fruits, vegetables and certain beverages. Flavonoids can be subdivided into different subgroups depending on the carbon of the C ring on which the B ring is attached and the degree of unsaturation and oxidation of the C ring. These subgroups are: flavones, flavonols, flavanones, flavanonols, flavanols or catechins, anthocyanins and chalcones. Flavonoids are now considered as an indispensable component in a variety of nutraceutical, pharmaceutical, medicinal and cosmetic applications. This is attributed to their anti-oxidative, anti-inflammatory, anti-mutagenic and anti-carcinogenic properties coupled with their capacity to modulate key cellular enzyme function. Naturally occurring flavonoids are known to have biological activities for use as drugs, for example, in diseases like cancer, Alzheimer’s disease (AD), atherosclerosis, etc. MCE offers a unique collection of 583 natural flavonoid compounds which is a useful tool for drug discovery as an important source of lead compounds.

Structure Classified Natural Product Libraries

98
HY-N0162 Luteolin
Luteolin (Luteoline), a flavanoid compound, is a potent Nrf2 inhibitor. Luteolin has anti-inflammatory, anti-cancer properties, including the induction of apoptosis and cell cycle arrest, and the inhibition of metastasis and angiogenesis, in several cancer cell lines, including human non-small lung cancer cells.
Keap1-Nrf2   Apoptosis   Autophagy   Endogenous Metabolite  
Lung Cancer   Colorectal Cancer   Ovarian Cancer   Digestive System Inflammation   Glucose Metabolism   Obesity  
96
HY-L028 CNS-Penetrant Compound Library
The blood-brain barrier (BBB) is the complex network of brain microvessels. It protects the brain from the external bloodstream environment and supplies the brain with the required nutrients for normal function. However, blood-brain barrier is also the obstacle to deliver beneficial drugs to treat CNS (central nervous system) diseases or brain tumors, as it has the least permeable capillaries in the entire body due to physical barriers (tight junctions). Therefore, it is crucial to discover drugs which can cross this barrier for the treatment of brain-based diseases, such as Alzheimer’s disease (AD), Parkinson’s disease (PD) and epilepsy. MCE offers a unique collection of 1,170 compounds with confirmed CNS-Penetrant property. It’s a useful tool for the discovery of drugs used for brain diseases, such as brain tumors, mental disorders, and neurodegenerative diseases.

Compound Characteristic Classified Libraries

91
HY-L003 Apoptosis Compound Library
Apoptosis is an ordered and orchestrated cellular process that occurs in physiological and pathological conditions, which is also called programmed cell death (PCD). Apoptosis plays a crucial role in developing and maintaining the health of the body by eliminating old cells, unhealthy cells and unnecessary cells. Too little or too much apoptosis contribute to many diseases. When apoptosis does not work correctly, cells that should be eliminated may persist and become immortal, for example, in cancer and leukemia. When apoptosis works overly well, it kills too many cells and inflicts grave tissue damage. This is the case in strokes and neurodegenerative disorders such as Alzheimer's, Huntington's, and Parkinson's disease. MCE designs a unique collection of 3,650 apoptosis-related compounds mainly focusing on the key targets in the apoptosis signaling pathway and can be used in the research of apoptosis signal pathway and related diseases.

Signaling Pathway Targeting Libraries

90
HY-L026 Clinical Compound Library
New drug development is a time-consuming and high-cost process. Drug repurposing (also called drug repositioning, reprofiling or re‑tasking) offers various advantages over developing an entirely new drug for a given indication, such as lower risk and less investment. Clinical drugs have confirmed bioactivities, clear mechanisms and high safety that are suitable for drug repurposing. MCE owns a unique collection of 2,568 clinical compounds that refer to various research areas including anti-cancer, anti-infection, anti-inflammation, nervous disease. Those compounds are of detailed information on clinical development status, research area, targets, etc.

Drug Repurposing Series

90
HY-L035P Drug Repurposing Compound Library Plus
New drug development is a time-consuming and high-cost process. Drug repurposing (also called drug repositioning, reprofiling or re‑tasking) offers various advantages over developing an entirely new drug for a given indication. First, the risk of failure is lower. Second, the time frame for drug development can be reduced. Third, less investment is needed. Approved and clinical drugs, especially after phase I drugs, have identified bioactivities, good pharmacokinetic characteristics and safety, which are suitable for drug repurposing. MCE Drug Repurposing Compound Library plus contains 6,142 approved and passed phase I clinical drugs, which have been completed extensive preclinical and clinical studies and have well-characterized bioactivities, safety and bioavailability properties. MCE Drug Repurposing Compound Library plus, with more powerful screening capability, further complement MCE Drug Repurposing Compound Library (HY-L035) by adding some compounds with low solubility or stability (Part B) to this library. All those supplementary compounds are supplied in powder form.

Drug Repurposing Series

89
HY-L010 MAPK Compound Library
MAPK families play an important role in complex cellular programs like proliferation, differentiation, development, transformation, and apoptosis. In mammalian cells, four MAPK families have been clearly characterized: ERK1/2, C-Jun N-terminal kinse/stress-activated protein kinase (JNK/SAPK) , p38 kinase and ERK5. They respond to different signals. Each MAPK-related cascade consists of three enzymes that are activated in series: a MAPK kinase kinase (MAPKKK), a MAPK kinase (MAPKK) and a MAP kinase (MAPK). MAPK signaling pathways has been implicated in the development of many human diseases including Alzheimer's disease (AD), Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS) and various types of cancers. MCE designs a unique collection of 1,154 MAPK signaling pathway inhibitors that act as a useful tool for MAPK-related drug screening and disease research.

Signaling Pathway Targeting Libraries

88
HY-L026P Clinical Compound Library Plus
New drug development is a time-consuming and high-cost process. Drug repurposing (also called drug repositioning, reprofiling or re‑tasking) offers various advantages over developing an entirely new drug for a given indication, such as lower risk and less investment. Clinical drugs have confirmed bioactivities, clear mechanisms and high safety that are suitable for drug repurposing. MCE owns a unique collection of 3,298 clinical compounds that refer to various research areas including anti-cancer, anti-infection, anti-inflammation, nervous disease. Those compounds are of detailed information on clinical development status, research area, targets, etc. Clinical Compound Library Plus, with powerful screening capability, further complements Clinical Compound Library (HY-L026) by adding some compounds with low solubility or solution stability (Part B) to this library. All those supplementary are supplied in powder form.

Drug Repurposing Series

86
HY-L086 Neurodegenerative Disease-related Compound Library
Neurodegenerative diseases are incurable and life-threatening conditions that result in progressive degeneration and/or death of nerve cells. Some common neurodegenerative diseases include Alzheimer’s Disease (AD), Parkinson’s Disease (PD), Motor Neuron Disease (MND), Huntington’s Disease (HD), Spino-Cerebellar Ataxia (SCA), Spinal Muscular Atrophy (SMA), and Amyotrophic Lateral Sclerosis (ALS). Because the pathophysiology of neurodegenerative disorders is generally poorly understood, it is difficult to identify promising molecular targets and validate them. At the same time, about 85% of the drugs fail in clinical trials. Therefore, validating new targets and discovering new drugs to mitigate neurodegenerative disorders is need of the hour. MCE offers a unique collection of 3,759 compounds with anti-Neurodegenerative Diseases activities or targeting the unique targets of neurodegenerative diseases. MCE Neurodegenerative Disease-related Compound Library is a useful tool for exploring the mechanism of neurodegenerative diseases and discovering new drugs for neurodegenerative diseases.

Disease Focused Libraries

85
HY-L134 Anti-Aging Natural Product Library
Aging is an unavoidable process, leading to cell senescence due to physiochemical changes in an organism. Aging cells cease to divide and drive the progression of illness through various pathways, resulting in the death of an organism ultimately. Anti-aging activities are primarily involved in the therapies of age-related disorders such as Parkinson's Disease (PD), Alzheimer's Disease (AD), cardiovascular diseases, cancer, and chronic obstructive pulmonary diseases. Natural products are known as effective molecules in anti-aging treatments, which delay the aging process through influencing several pathways and thus ensure an extended lifespan. MCE offers a unique collection of 193 natural products with validated anti-aging activity. MCE anti-aging natural product library is a useful tool for the study of aging-related diseases drugs and pharmacology.

Natural Product Screening Libraries Disease Focused Libraries

85
HY-L040 Anti-diabetic Compound Library
Diabetes mellitus, usually called diabetes, is a group of metabolic disorders characterized by a high blood sugar level over a prolonged period of time. The most common types are Type I and Type II. Type I diabetes (T1D), also called juvenile onset diabetes mellitus or insulin-dependent diabetes mellitus, is characterized by destruction of the β-cells of the pancreas and insulin is not produced, whereas type II diabetes (T2D), also called non-insulin-dependent diabetes mellitus, is characterized by a progressive impairment of insulin secretion and relative decreased sensitivity of target tissues to the action of this hormone. Type 2 diabetes accounts for the vast majority of all diabetes mellitus. Diabetes of all types can lead to complications in many parts of the body and can increase the overall risk of dying prematurely. Possible complications include kidney failure, leg amputation, vision loss and nerve damage. The pathogenesis of diabetes is complicated, and development of the safe and effective drugs against diabetes is full of challenge. Increasing studies have confirmed that the pathogenesis of diabetes is related to various signaling pathways, such as insulin signaling pathway, AMPK pathway, PPAR regulation and chromatin modification pathways. These signaling pathways have thus become the major source of the promising novel drug targets to treat metabolic diseases and diabetes. MCE Anti-diabetic Compound Library owns a unique collection of 1,172 compounds, which mainly target SGLT, PPAR, DPP-4, AMPK, Dipeptidyl Peptidase, Glucagon Receptor, etc. This library is a useful tool for discovery anti-diabetes drugs.

Disease Focused Libraries

84
HY-L053 NMPA-Approved Drug Library
From target identification to clinical research, traditional drug discovery and development is a time-consuming and costly process, which also bears high risk. Compared with traditional drug discovery, drug repositioning or repurposing, also known as old drugs for new uses can greatly shorten the development cycle and reduce development cost, which has become a new trend of drug development. After undergoing clinical trials, approved drugs have identified bioactivities, good pharmacokinetic characteristics and safety, which can greatly improve the success rate of drug discovery. A number of successes have been achieved, such as metformin for type 2 diabetes and thalidomide for leprosy and multiple myeloma, etc. MCE provides a unique collection of 1,534 China NMPA (National Medical Products Administration) approved compounds, which have undergone extensive preclinical and clinical studies and have well-characterized bioactivities, safety and bioavailability properties. MCE NMPA-Approved Drug Library is a good tool for drug repurposing which could dramatically accelerate drug development.

Drug Repurposing Series

84
HY-L069 Anti-Alzheimer's Disease Compound Library
Alzheimer’s Disease (AD) is a progressive degenerative brain disease which causes mental and physical decline, gradually resulting in death. Despite the significant public health issue that it poses, only few medical treatments have been approved for Alzheimer’s Disease (AD) and these act to control symptoms rather than alter the course of the disease. Discovery of new therapeutic approaches depends on the study of pathology of AD. Recent research findings have led to greater understanding of disease neurobiology in Alzheimer's Disease (AD) and identification of unique targets for drug development. Several important mechanisms have been proposed to explain the underlying pathology of AD, such as Amyloid cascade hypothesis, Tau hypothesis and Cholinergic hypothesis, etc. MCE offers a unique collection of 2,174 compounds with anti-Alzheimer’s Disease activities or targeting the unique targets of AD. MCE Anti-Alzheimer’s Disease Compound Library is a useful tool for exploring the mechanism of AD and discovering new drugs for AD.

Disease Focused Libraries

84
HY-L070 Neuroprotective Compound Library
Neurodegenerative diseases are characterised by progressive dysfunction and death of neurons, such as Alzheimer’s disease, Parkinson’s disease, and multiple sclerosis (MS). Neuroprotection is an approach to preserve neurons so that neurons cannot be hurt by different pathological factors in neurodegenerative diseases. Neuroprotectors are some agonists and antagonists targeting some key targets in neuroprotactive signal pathways, such as calcium and sodium channel blockers, GABA receptor agonists, NMDA receptor Antagonists, etc. Current neuroprotectors cannot reverse existing damage, but they may protect against further nerve damage and slow down any degeneration of the central nervous system (CNS) and still play important roles in the treatment of neurodegenerative diseases. MCE offers a unique collection of 1,851 compounds with potential neuroprotective activities. These compounds mainly act on some key targets in neuroprotetive signal pathways, such as calcium channel, sodium channel, adenosine A1 receptor, etc. MCE Neuroprotective Compopund Library is a useful tool in neuroprotective drug discovery.

Compound Characteristic Classified Libraries

84
HY-L094 Food-Sourced Compound Library
The health benefits deriving from the consumption of certain foods have been common knowledge. All foods are made up of chemical substances. Chemicals in foods are largely harmless and often desirable. At present, numerous researchers have been focused on the beneficial role played by certain food components in the close relationship between food intake and health status. For example, polyphenols, a common class of compounds among foods, are well-known antioxidants, which may play a role in the prevention of several diseases including type 2 diabetes, cardiovascular diseases, and some types of cancer. MCE supplies a unique collection of 2,064 compounds from variety of foods. All compounds are with specific food source(s). MCE Food-Sourced Compound Library is the useful tool to discover molecules with pharmaceutical activity from foods.

Compound Characteristic Classified Libraries

84
HY-L116 EMA-Approved Drug Library
MCE EMA-Approved Drug Library consists of 728 EMA-approved drugs with high pharmacological diversity. All drugs in this library have been completed extensive preclinical and clinical studies and have well-characterized bioactivities, safety and bioavailability properties. MCE EMA-Approved Drug Library is a useful tool for drug repurposing which could dramatically accelerate drug development.

Drug Repurposing Series

84
HY-L034M Anti-Aging Compound Library Mini
Research has shown that drugs targeting aging pathways demonstrate promising potential in models of age-related diseases such as Alzheimer's disease, cardiovascular diseases, metabolic syndrome, osteoarthritis, and various malignancies. This suggests that intervening in the biological processes of aging may enable synergistic prevention and treatment of multiple chronic diseases. Against the backdrop of the gradual elucidation of core aging mechanisms-including cellular senescence, telomere attrition, epigenetic dysregulation, and chronic inflammation anti-aging research has shifted from traditional phenotypic interventions toward targeting key pathways that regulate biological age. The MCE Anti-Aging Compound Library Mini is precisely built upon this cutting-edge concept. It focuses on aging-related targets validated through genetic or functional studies, comprising 381 compounds designed to provide systematic research tools for aging biology and intervention strategy development. The library covers core mechanisms such as mTOR, SIRT, energy metabolism, clearance of senescent cells, optimization of mitochondrial function, and telomere maintenance. For each target, 1-5 compounds with clear activity and strong representativeness have been carefully selected, spanning the entire translational spectrum from preclinical tool molecules to clinically investigational drugs.

Disease Focused Libraries

83
HY-L087 Anti-Obesity Compound Library
Obesity is widely recognized as the largest and fastest growing public health problem and is associated with numerous chronic disorders including osteoarthritis, obstructive sleep apnea, gallstones, fatty liver disease, reproductive and gastrointestinal cancers, dyslipidemia, hypertension, type 2 diabetes, heart failure, coronary artery disease, stroke, etc. Although obesity has long been associated with serious health issues, it has only recently been regarded as a disease in the sense of being a specific target for medical therapy. Obesity may be viewed as the dysregulation of two physiological functions, appetite regulation and energy metabolism, which combine to create disordered energy balance. Consequently, developing obesity treatments that target novel pathways is a growing focus for both biopharmaceutical industries. MCE Anti-Obesity Compound Library owns a unique collection of 3,741 compounds, which mainly target signaling pathway of controlling appetite, fatty acid metabolism and energy expenditure, etc. This library is a useful tool for discovery anti-obesity drugs.

Disease Focused Libraries

83
HY-L098 Drug Metabolite Library
A drug metabolite is a byproduct of the body breaking down, or “metabolizing” a drug into a different substance. Most drugs undergo chemical alteration by various bodily systems as a way to create compounds that are more easily excreted from the body. Drugs can be metabolized by oxidation, reduction, hydrolysis, hydration, conjugation, condensation, or isomerization. Drug metabolism can produce metabolites with physicochemical and pharmacological properties that differ substantially from those of the parent drug, and consequently have important implications for both drug safety and efficacy. MCE offers a unique collection of 440 drug metabolites which is a useful tool for drug safety and efficacy study and drug repurposing.

Compound Characteristic Classified Libraries

83
HY-L104 Pediatric Drug Library
The lack of availability of appropriate medicines for children is an extensive and urgent problem. A variety of obstacles hinder children's drug development, including the limited commercial interest, lack of suitable infrastructure and competence for conducting paediatric clinical trials, difficulties in trial design, ethical worries and many others. Because of these factors, unlicensed and off-label prescribing is very common in children which may lead to safety concern. MCE offers a unique collection of 712 Pediatric medicines, all of which have been approved or studied in clinical trials for children diseases. MCE children’s drug library is a useful tool for drug repurposing to discover new children’s indications.

Drug Repurposing Series

83
HY-L141 Off-patent Drug Library
Drug repurposing (also called drug repositioning, reprofiling, or re‑tasking) offers various advantages over developing an entirely new drug for a given indication, for example, lower risk of failure, less investment, and shorter development timelines. But drug repositioning projects are also subject to several risks, including regulatory and intellectual property issues. So the off-patent drugs are optimal for repositioning because of their immediate availability for clinical studies, with high feasibility and relatively low risk. MCE carefully prepared a unique collection of 2,921 off-patent drugs, which is a good choice for drug repurposing.

Drug Repurposing Series

83
HY-L228 Lipid Metabolite Compound Library
Lipids are important energy storage substances in the human body. They are involved in the regulation of cell structure and function, as well as signaling pathways and gene expression. Abnormal lipid levels in tissues or their dysregulation can lead to various diseases. These include obesity, type 2 diabetes, non-alcoholic fatty liver disease, neurodegenerative diseases, infections, and cancer. Therefore, maintaining normal levels of lipid metabolism is critical to overall health. One of the key features of cancer is aberrant lipid metabolism. This includes alterations in lipid uptake, lipid desaturation, neolipogenesis, lipid droplets, and fatty acid oxidation in cancer cells. These changes all contribute to cellular survival in an ever-changing microenvironment. They do this by modulating feed-forward oncogenic signals and key oncogenic functions. Additionally, they affect oxidative stress, other types of stress, immune responses, and intercellular communication. Alterations in lipid metabolism have a strong impact on the properties of cancer stem cells. This includes aspects such as self-renewal, differentiation, invasion, metastasis, drug sensitivity, and resistance. Furthermore, these alterations also modulate T cell responses. MCE can offer 146 metabolites of lipid metabolism pathways, which can be used for drug screening in cancer, immune-based diseases, metabolic diseases, and other diseases.

Metabolism Focused Libraries

83
HY-L241 Chinese Baijiu Compound Library
Chinese Baijiu is one of the oldest alcoholic beverages in the world, with a history of over 2,000 years. It can be classified into 12 aroma types based on its fragrance and flavor characteristics. The specific flavor profile of Baijiu is determined by the composition and concentration of certain compounds. These trace compounds, present in low concentrations yet rich in esters, alcohols, acids, lactones, aldehydes, ketones, acetals, alkenes, and others, significantly influence the flavor of Baijiu. Additionally, some active components in Baijiu possess antioxidant properties, and moderate consumption may help reduce the risk of cardiovascular diseases, dementia, and insulin resistance. Therefore, studying the chemical composition of Baijiu is crucial for promoting its fermentation process and enhancing its flavor and quality. MCE has compiled included 674 Chinese Baijiu components, which can be used for drug development, Baijiu fermentation, and research related to Baijiu flavor and aroma.

Compound Characteristic Classified Libraries

83
HY-L920 CNS MPO Lead-like Library
With the aging population and increasing competitive pressures, neurodegenerative diseases of the central nervous system (CNS) have become a serious medical challenge in modern society, including Parkinson's disease, Alzheimer's disease, brain tumors, and multiple sclerosis. The CNS MPO (Multi-Parameter Optimization) score is a widely recognized algorithm in medicinal chemistry. Developed by Pfizer, this method is based on an analysis of approved CNS drugs and their interior CNS drug candidates, establishing the CNS MPO rules. It incorporates six key physicochemical properties (ClogP, ClogD, MW, TPSA, HBD, and pKa) to prospectively optimize CNS drug attributes—such as high blood-brain barrier (BBB) permeability, low P-gp efflux liability, low metabolic clearance, and high safety—thereby improving the clinical success rate of CNS drug candidates. The CNS MPO compound library is a collection of compounds with CNS MPO scores greater than 5, specifically designed for CNS drug discovery.

Focused and target libraries

83
HY-13755 Sulforaphane
Sulforaphane is an orally active inducer of the Keap1/Nrf2/ARE pathway. Sulforaphane promotes the transcription of tumor-suppressing proteins and effectively inhibits the activity of HDACs. Through the activation of the Keap1/Nrf2/ARE pathway and further induction of HO-1 expression, Sulforaphane protects the heart. Sulforaphane suppresses high glucose-induced pancreatic cancer through AMPK-dependent signal transmission. Sulforaphane exhibits both anticancer and anti-inflammatory properties.
HDAC   Keap1-Nrf2   Apoptosis   Bcl-2 Family   Caspase   Reactive Oxygen Species (ROS)  
Inflammation or Immune System Disease  
79
HY-16569 Colchicine
Colchicine, an orally active alkaloid, is a potent tubulin inhibitor and a microtubule disrupting agent. Colchicine inhibits microtubule polymerization with an IC50 of 3 nM. Colchicine is also a competitive antagonist of the α3 glycine receptors (GlyRs). Colchicine prevents non-steroidal anti-inflammatory drug (NSAID)-induced small intestinal injury by inhibiting activation of the NLRP3 inflammasome. Colchicine has extensive anti-inflammatory, immunosuppressive and strong anti-fibrosis effects and has the potential for gouty arthritis research.
Environmental Pollutants   Microtubule/Tubulin   Autophagy   Apoptosis   NOD-like Receptor (NLR)  
Digestive System Disease   Lung Cancer   Prostate Cancer   Viral Infection   Coronavirus Infection   Depression   Pain   Autoimmune Disease   Digestive System Inflammation   Alzheimer's Disease   Lung Fibrosis  
77
HY-19370 FPS-ZM1
FPS-ZM1 is a high-affinity and BBB-permeable RAGE inhibitor with a Ki of 25 nM.
Amyloid-β  
Alzheimer's Disease  
73
HY-13323 CX-5461
CX-5461 is a selective, orally active RNA polymerase I inhibitor. CX-5461 disrupts the formation of the SL1-rDNA complex, thereby blocking the transcription initiation of ribosomal RNA without altering the activity of RNA polymerase II, DNA replication, or protein translation processes. CX-5461 upregulates the expression of p21, MDM2, Sestrin1/2, and phosphorylated AMPKα, and reduces the level of phosphorylated Akt. CX-5461 induces G2/G2/M cell cycle arrest, Autophagy, Apoptosis, and cellular senescence, and activates CHK1, CHK2, and RPA. CX-5461 can be used in research related to osteosarcoma, cervical cancer, hematologic malignancies, high-grade serous ovarian cancer, and solid tumors.
DNA/RNA Synthesis   MDM-2/p53   AMPK   Akt   Autophagy   Apoptosis   Checkpoint Kinase (Chk)  
Musculoskeletal and Skin Disease   Cervical Cancer   Ovarian Cancer   Osteosarcoma  
72
HY-17363 Dimethyl fumarate
Dimethyl fumarate (DMF) is an orally active and brain-penetrant Nrf2 activator and induces upregulation of antioxidant gene expression. Dimethyl fumarate induces necroptosis in colon cancer cells through GSH depletion/ROS increase/MAPKs activation pathway, and also induces cell autophagy. Dimethyl fumarate can be used for multiple sclerosis research.
Keap1-Nrf2   Reactive Oxygen Species (ROS)   HIV   Autophagy   Endogenous Metabolite  
Neurological, Eye or Ear Disease   Inflammation or Immune System Disease   Colorectal Cancer   Viral Infection   Obesity   Lung Fibrosis  
65
HY-10191 Linsitinib
Linsitinib (OSI-906) is a potent, selective and orally bioavailable dual inhibitor of the IGF-1 receptor and insulin receptor (IR) with IC50s of 35 and 75 nM, respectively.
IGF-1R   Insulin Receptor  
Lung Cancer   Prostate Cancer   Pancreatic Cancer   Glucose Metabolism   SARS-CoV-2 Infection  
52
HY-P0128 β-Amyloid (25-35)
β-Amyloid (25-35) (Amyloid beta-peptide (25-35)) is the fragment Aβ(25-35) of the Alzheimer's amyloid β-peptide, has shown neurotoxic activities in cultured cells.
Amyloid-β  
51
HY-114118B Semaglutide acetate
Semaglutide acetate is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide acetate promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide acetate also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide acetate has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide acetate can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer.
GLP Receptor   Apoptosis   Bcl-2 Family   α-synuclein   Autophagy   Insulin Receptor   p38 MAPK  
Cancer   Neurological, Eye or Ear Disease   Metabolic or Endocrine Disease  
50
HY-114118A Semaglutide TFA
Semaglutide TFA is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide TFA promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide TFA also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide TFA has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide TFA can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer.
GLP Receptor   Apoptosis   Bcl-2 Family   α-synuclein   Autophagy   Insulin Receptor   p38 MAPK  
Neurological, Eye or Ear Disease   Metabolic or Endocrine Disease  
50
HY-114118 Semaglutide
Semaglutide is a long-acting, selective, competitive GLP-1R agonist that can penetrate the blood-brain barrier. After activating GLP-1R, Semaglutide promotes insulin secretion, inhibits gastric emptying and appetite, and at the same time enhances autophagy, inhibits oxidative stress and apoptosis. Semaglutide also regulates mitochondrial function and lipid metabolism (such as reducing de novo lipogenesis in the liver). Semaglutide has activities such as lowering blood sugar, reducing weight, neuroprotection (such as improving motor function in Parkinson's disease models, reducing α-synuclein aggregation) and improving hepatic steatosis. Semaglutide can be used for the study of neurodegenerative diseases and liver diseases such as type 2 diabetes, obesity, Parkinson's disease, metabolic associated fatty liver disease (MASLD), and cancer.
GLP Receptor   Apoptosis   Bcl-2 Family   α-synuclein   Autophagy   Insulin Receptor   p38 MAPK  
Cancer   Neurological, Eye or Ear Disease   Metabolic or Endocrine Disease  
50
HY-50662 A-769662
A-769662 is a AMP-activated protein kinase (AMPK) activator. A-769662 inhibits the function of the 26S proteasome by an AMPK-independent mechanism and leads to cell cycle arrest. A-769662 directly stimulates partially purified rat liver AMPK (EC50 = 0.8 μM) and inhibits fatty acid synthesis in primary rat hepatocytes (IC50 = 3.2 μM). A-769662 can alleviate the symptoms of metabolic diseases such as type 2 diabetes.
AMPK  
Pancreatic Cancer   Pain   Digestive System Inflammation   Glucose Metabolism   Obesity  
48
HY-16966 SBI-0206965
SBI-0206965 is a potent, selective and cell permeable autophagy kinase ULK1 inhibitor with IC50s of 108 nM for ULK1 kinase and 711 nM for the highly related kinase ULK2. SBI-0206965 is also an AMPK inhibitor that can paradoxically increase Thr172 phosphorylation.
ULK   AMPK   Autophagy   Apoptosis  
Pancreatic Cancer   Ovarian Cancer   Pain   Digestive System Inflammation  
44
HY-15656 Ceritinib
Ceritinib (LDK378) is a selective, orally bioavailable, and ATP-competitive ALK tyrosine kinase inhibitor with an IC50 of 200 pM. Ceritinib also inhibits IGF-1R, InsR, and STK22D with IC50 values of 8, 7, and 23 nM, respectively. Ceritinib shows great antitumor potency.
Anaplastic lymphoma kinase (ALK)   Insulin Receptor   IGF-1R  
Metabolic or Endocrine Disease   Respiratory Disease   Prostate Cancer   Leukemia/Lymphoma/Myeloma   Pancreatic Cancer   Non-Small Cell Lung Cancer  
43
HY-P0014 Liraglutide
Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used clinically to treat type 2 diabetes mellitus.
GCGR   GLP Receptor  
Digestive System Disease   Digestive System Inflammation   Alzheimer's Disease   Parkinson's Disease   Type 1 Diabetes   Psoriasis   Chronic Obstructive Pulmonary Disease   Type 2 Diabetes   Obesity  
43
HY-12497 ANA-12
ANA-12 is a brain-penetrant, selective TrkB antagonist with IC50 values of 45.6 nM and 41.1 μM, and Kd values of 10 nM and 12 μM, for high- and low-affinity sites, respectively. ANA-12 specifically inhibits BDNF-induced TrkB receptor activation and its downstream signaling cascades by directly and non-competitively binding to the TrkB receptor, without affecting the functions of TrkA and TrkC. ANA-12 is used in research concerning neuropsychiatric disorders (such as depression and anxiety), acute and chronic pain, neuroimmune inflammation, and the mechanisms of learning and memory.
Trk Receptor   NOD-like Receptor (NLR)   AIM2   Caspase  
Depression   Anxiety or Fear-Related Disease   Pain   CNS Infection   Behavioral Addiction  
41
HY-N0148 Rutin
Rutin (Rutoside) is a flavonoid found in many plants and shows a wide range of biological activities including anti-inflammatory, antidiabetic, antioxidant, neuroprotective, nephroprotective, hepatoprotective and reducing Aβ oligomer activities. Rutin is also a CBR1 inhibitor, which can cross the blood brain barrier. Rutin attenuates vancomycin-induced renal tubular cell apoptosis via suppression of apoptosis, mitochondrial dysfunction, and oxidative stress.
Amyloid-β   Autophagy   Apoptosis   Endogenous Metabolite  
Cancer   Digestive System Disease   Digestive System Inflammation   Glucose Metabolism   SARS-CoV-2 Infection   Alzheimer's Disease   Parkinson's Disease  
35
HY-D0218 Thioflavin T
Thioflavin T is a cationic Benzothiazole dye that shows enhanced fluorescence upon binding to amyloid in tissue sections. Excitation max.: ~385 nm (free); ~450 nm (bound); Emission max.: ~445 nm (free); ~485 nm (bound).
Amyloid-β  
32
HY-14536 Methylene Blue
Methylene blue (Basic Blue 9) is a guanylyl cyclase (sGC), monoamine oxidase A (MAO-A) and NO synthase (NOS) inhibitor. Methylene blue is a vasopressor and is often used as a dye in several medical procedures. Methylene blue through the nitric oxide syntase/guanylate cyclase signalling pathway to reduce prepulse inhibition. Methylene blue is a REDOX cycling compound and able to cross the blood-brain barrier. Methylene blue is a Tau aggregation inhibitor. Methylene Blue is a photosensitizer and redox agent. Methylene blue reduces cerebral edema, attenuated microglial activation and reduced neuroinflammation.
Environmental Pollutants   Microtubule/Tubulin   Guanylate Cyclase   Monoamine Oxidase   NO Synthase  
Infection   Neurological, Eye or Ear Disease   Breast Cancer  
30
HY-N0142 Phloretin
Phloretin (NSC 407292; RJC 02792) is a flavonoid extracted from Malus pumila Mill.，has anti-inflammatory activities. Phloridzin is a specific，competitive and orally active inhibitor of sodium/glucose cotransporters in the intestine (SGLT1) and kidney (SGLT2). Phloretin inhibits Yeast-made GLUT1 as well as Human erythrocyte GLUT1 with IC50values of 49 μM and 61 μM，respectively.Phloretin has the potential for the treatment of rheumatoid arthritis (RA) and allergic airway inflammation.
SGLT   Endogenous Metabolite   GLUT  
Cancer   Digestive System Disease   Digestive System Inflammation   Obesity   Rheumatoid Arthritis  
29
HY-P1363B β-Amyloid (1-42), human, HFIP-treated
β-Amyloid (1-42), human, HFIP-treated, a 42-amino acid peptide that has been treated with HFIP from β-Amyloid (1-42), human (HY-P1363A), is a brain-penetrant amyloid protein fragment, which can be used in research on Alzheimer's disease and Down’s syndrome. β-Amyloid (1-42), human, HFIP-treated remaining as a monomer exhibits antioxidant and neuroprotective effects. β-Amyloid (1-42), human, HFIP-treated, after being dissolved in DMSO to form the stock solution, on the one hand, can form soluble oligomers (AβOs) when incubated at 4°C, which have synaptic toxicity and neurotoxicity; on the other hand, it can be incubated at 37°C to form insoluble fibrils, with lower neurotoxicity, and participating in the oxidative damage process. Aβ42 oligomers bind to various neuronal surface receptors (such as PrPc, mGluR5, NMDA receptors, etc.), triggering oxidative stress, calcium homeostasis imbalance, and synaptic toxicity via activating downstream signaling pathways, leading to neuronal dysfunction and death.
Amyloid-β  
Alzheimer's Disease  
27
HY-P1363A β-Amyloid (1-42), human
β-Amyloid (1-42) (Amyloid β-peptide (1-42)), human, a 42-amino acid peptide that has not been treated with HFIP, is a brain-penetrant amyloid protein fragment, which can be used in research on Alzheimer's disease and Down’s syndrome. β-Amyloid (1-42), human remaining as a monomer exhibits antioxidant and neuroprotective effects. β-Amyloid (1-42), human, after being monomericized by HFIP and dissolved in DMSO to form the stock solution, on the one hand, can form soluble oligomers (AβOs) when incubated at 4 °C, which have synaptic toxicity and neurotoxicity; on the other hand, it can be incubated at 37 °C to form insoluble fibrils, with lower neurotoxicity, and participating in the oxidative damage process. Aβ42 oligomers bind to various neuronal surface receptors (such as PrPc, mGluR5, NMDA receptors, etc.), triggering oxidative stress, calcium homeostasis imbalance, and synaptic toxicity via activating downstream signaling pathways, leading to neuronal dysfunction and death.
Amyloid-β  
Alzheimer's Disease  
27
HY-12212 Omaveloxolone
Omaveloxolone (RTA 408) is an antioxidant inflammation modulator (AIM), which activates Nrf2 and suppresses nitric oxide (NO). Omaveloxolone attenuates osteoclastogenesis by inhibiting STING dependent NF-κb signaling.
Keap1-Nrf2   STING   Apoptosis  
Cancer   Digestive System Disease   Digestive System Inflammation   Obesity   Lung Fibrosis  
26
HY-16900 Rolipram
Rolipram is a PDE4 inhibitor, with blood-brain barrier permeability, that reverses β-amyloid-induced learning and memory impairment in rats. Rolipram elevates intracellular cAMP and clevels and regulates the cAMP/CREB signaling pathway, thereby alleviating neuroinflammation and apoptotic responses. Rolipram promotes neuronal differentiation of human bone marrow mesenchymal stem cells and inhibits Methamphetamine- and morphine-induced hyperlocomotion in mice. Rolipram also reduces the viability of glioblastoma stem-like cells and enhances Bevacizumab (HY-P9906)-induced cell death. Rolipram inhibits the expression of proinflammatory cytokines and enhances central noradrenergic transmission. Rolipram is mainly used in studies related to various central nervous system diseases including Alzheimer's disease, major depressive disorder, glioblastoma multiforme, and multiple sclerosis.
Bacterial   HIV   Phosphodiesterase (PDE)   Epigenetic Reader Domain   Amyloid-β  
Colorectal Cancer   Bacterial Infection   Depression   SARS-CoV-2 Infection   Alzheimer's Disease   Huntington's Disease   HIV-1 Infection  
19
HY-156498 RMC-7977
RMC-7977 is an orally active triple-complex RAS inhibitor that can simultaneously bind to cyclophilin A (CYPA) (Kd = 195 nM) and KRAS (G12V) (Kd = 292 μM). It exhibits broad-spectrum inhibitory activity against KRAS, NRAS, and HRAS proteins and their various wild-type and mutant variants. RMC-7977 induces apoptosis by inhibiting the phosphorylation of ERK, CRAF, and RSK, as well as increasing PARP cleavage. This leads to tumor regression, reduces resistance in KRASG12C cancer models, and demonstrates good tolerability across various RAS cancer models.
Ras   ERK   Raf   Ribosomal S6 Kinase (RSK)   AMPK   Apoptosis   PARP  
18
HY-N0045 Ginsenoside Rg1
Ginsenoside Rg1 is one of the major active components of Panax ginseng. Ginsenoside Rg1 ameliorates the impaired cognitive function, displays promising effects by reducing cerebral Aβ levels. Ginsenoside Rg1 also reduces NF-κB nuclear translocation.
Amyloid-β   NF-κB   Apoptosis  
Breast Cancer   Prostate Cancer   Liver Cancer   Leukemia/Lymphoma/Myeloma   Pancreatic Cancer   Ovarian Cancer   Depression   Pain   Digestive System Inflammation   Alzheimer's Disease   Obesity  
17
HY-P1156 Insulin(cattle)
Insulin cattle is a two-chain polypeptide hormone produced in vivo in the pancreatic β cells. Insulin cattle has often been used as growth supplement in culturing cells.
Insulin Receptor  
Metabolic or Endocrine Disease  
17
HY-15136 Lonafarnib
Lonafarnib (Sch66336) is an orally active, blood-brain barrier penetrant farnesyltransferase (FPTase) inhibitor. Lonafarnib increases the phosphorylation levels of Akt, CaMKII and CREB, upregulates BDNF expression in the hippocampus, elevates the content of α7nAChR on cell membranes, and blocks the isoprenylation of H-Ras. Lonafarnib repairs synapses and reverses spatial memory deficits in Aβ1-42 model mice. Lonafarnib inhibits RSV fusion and replication, and alleviates virus-induced lung injury. Lonafarnib activates the lysosomal and autophagic pathways, and reduces the phosphorylation and aggregation of tau. Lonafarnib acts synergistically with Sorafenib (HY-10201) to promote apoptosis, and inhibits the proliferation and invasion of melanoma cells. Lonafarnib inhibits the farnesylation of progerin, repairs nuclear membrane defects, and activates the cGAS-STING-STAT1 signaling pathway. Lonafarnib can be used in research related to diseases including Alzheimer's disease, viral infections, melanoma, and progeria.
Farnesyl Transferase   Tau Protein   RSV   Akt   Ras   Bcl-2 Family   STAT   nAChR   Apoptosis   Autophagy  
Melanoma   Viral Infection   Alzheimer's Disease  
14
HY-W015229 3-Indolepropionic acid
3-Indolepropionic acid is shown to be a powerful antioxidant and has potential in the treatment for Alzheimer’s disease.
Endogenous Metabolite   Reactive Oxygen Species (ROS)  
Glucose Metabolism   Alzheimer's Disease  
13
HY-W250154 β-Nicotinamide adenine dinucleotide reduced dipotassium
β-Nicotinamide adenine dinucleotide reduced dipotassium is an orally effective reduced coenzyme. β-Nicotinamide adenine dinucleotide reduced dipotassium plays a role in regenerating electron donors during cellular energy metabolism, including glycolysis, β-oxidation, and the tricarboxylic acid (TCA) cycle. β-Nicotinamide adenine dinucleotide reduced dipotassium regulates calcium homeostasis by promoting the opening of IP3-gated Ca2+ channels and inhibiting Ryanodine receptor, and affects mitochondrial function through direct interaction with VDAC. β-Nicotinamide adenine dinucleotide reduced dipotassium is used in cytoprotective studies related to cerebral ischemic injury, neurodegenerative diseases, aging, and signal transduction.
Endogenous Metabolite   Calcium Channel   VDAC  
Neurodegenerative Disease   Cerebrovascular Disease   Cellular Senescence  
11
HY-F0001 NADH disodium salt
NADH disodium salt (Disodium NADH) is an orally effective reduced coenzyme. NADH disodium salt plays a role in regenerating electron donors during cellular energy metabolism, including glycolysis, β-oxidation, and the tricarboxylic acid (TCA) cycle. NADH disodium salt regulates calcium homeostasis by promoting the opening of IP3-gated Ca2+ channels and inhibiting Ryanodine receptor, and affects mitochondrial function through direct interaction with VDAC. NADH disodium salt is used in cytoprotective studies related to cerebral ischemic injury, neurodegenerative diseases, aging, and signal transduction.
Endogenous Metabolite   Calcium Channel   VDAC  
Neurodegenerative Disease   Cerebrovascular Disease   Cellular Senescence  
11
HY-B0130 Perindopril
Perindopril erbumine is an angiotensin-converting enzyme inhibitor. Perindopril erbumine modulates NFκB and STAT3 signaling and inhibits glial activation and neuroinflammation. Perindopril erbumine can be used for the research of Chronic Kidney Disease and high blood pressure.
Angiotensin-converting Enzyme (ACE)   NF-κB   STAT   Sirtuin  
Lung Cancer   Breast Cancer   Prostate Cancer   Pancreatic Cancer   Pain   Digestive System Inflammation   Hypertension  
8
HY-B0158 Cytidine
Cytidine is a pyrimidine nucleoside and acts as a component of RNA. Cytidine is a precursor of uridine. Cytidine controls neuronal-glial glutamate cycling, affecting cerebral phospholipid metabolism, catecholamine synthesis, and mitochondrial function.

Source: Widespread

Nucleoside Antimetabolite/Analog   Endogenous Metabolite  
Neurological, Eye or Ear Disease   Lung Cancer   Leukemia/Lymphoma/Myeloma   SARS-CoV-2 Infection  
8
HY-B1521 Aluminum Hydroxide
Aluminum Hydroxide is an orally active main form of aluminum used as adjuvant. Aluminum hydroxide-based adjuvant researches include the repository effect, pro-phagocytic effect, and activation of the pro-inflammatory NLRP3 pathway. Aluminum Hydroxide also acts as adjuvant to compensate low inherent immunogenicity of subunit vaccines.
Environmental Pollutants   NOD-like Receptor (NLR)  
Inflammation or Immune System Disease   Blood or Cardio-cerebrovascular Disease  
7
HY-19948 Leucomethylene blue mesylate
Leucomethylene blue (TRx0237) mesylate, an orally active second-generation tau protein aggregation inhibitor (Ki of 0.12 μM), could be used for the study of Alzheimer's Disease. Leucomethylene blue mesylate is a common reduced form of Methylene Blue, Methylene Blue is a member of the thiazine class of dyes.
Tau Protein  
Neurological, Eye or Ear Disease  
6
HY-N2195 Nootkatone
Nootkatone, a neuroprotective agent from Vitis vinifera, has antioxidant and anti-inflammatory effects. Nootkatone improves cognitive impairment in lipopolysaccharide-induced mouse model of Alzheimer's disease.
Environmental Pollutants   TNF Receptor   Interleukin Related  
Digestive System Disease   Prostate Cancer   Depression   Digestive System Inflammation   Alzheimer's Disease   Lung Fibrosis   Rheumatoid Arthritis  
4
HY-N7109 Erucic acid
Erucic acid, a monounsaturated fatty acid (MUFA), is isolated from the seed of Raphanus sativus L. Erucic acid can readily cross the blood-brain barrier (BBB), it has been reported to normalize the accumulation of very long-chain fatty acids in the brain. Erucic acid can improve cognitive impairment and be effective against dementia.
PI3K   Endogenous Metabolite  
Alzheimer's Disease  
4
HY-N0385 Gomisin J
Gomisin J is a Schisandra chinensis-derived lignan that can inhibit multiple targets such as eNOS, AMPK (LKB1, CaMKIIβ), fetuin-A, NF-κB, Nrf2/HO-1, and can pass through the blood-brain barrier. Gomisin J increases NO bioavailability by activating eNOS, regulates lipid metabolism by activating the AMPK pathway, inhibits fetuin-A and NF-κB to exert anti-inflammatory effects, and activates Nrf2/HO-1 to enhance antioxidant capacity. Gomisin J has the activities of anti-hypertension, regulating liver lipid metabolism, and reducing cerebral ischemia-reperfusion injury, and can be used for research on hypertension, non-alcoholic fatty liver disease, cerebral ischemia-reperfusion injury, etc.
NO Synthase   NF-κB   CaMK   AMPK   Keap1-Nrf2  
Breast Cancer   Prostate Cancer   Liver Cancer   Leukemia/Lymphoma/Myeloma   Pancreatic Cancer   Ovarian Cancer   Depression   Pain   Ischemia-Reperfusion Injury   Nonalcoholic Steatohepatitis   Hypertension   Obesity   Lung Fibrosis  
3
HY-N7981 Pratensein
Pratensein, a flavonoid, ameliorates β-amyloid-induced cognitive impairment in rats via reducing oxidative damage and restoring synapse and BDNF levels.
NF-κB  
Breast Cancer   Prostate Cancer   Liver Cancer   Leukemia/Lymphoma/Myeloma   Pancreatic Cancer   Ovarian Cancer   Depression   Pain   Digestive System Inflammation   Alzheimer's Disease   Obesity  
3
HY-N0464 D-(-)-Quinic acid
D-(-)-Quinic acid scavenges hydrogen peroxide (IC50=87.11 μg/mL) and exhibits antioxidant activity. D-(-)-Quinic acid is the inhibitor for MAO and α-Glucosidase (IC50 =93.75 μg/mL). D-(-)-Quinic acid is orally active.

Source: Widespread

Endogenous Metabolite   Glycosidase   Monoamine Oxidase  
Neurodegenerative Disease   Obesity  
3
HY-W004284 Heptadecanoic acid
Heptadecanoic acid is an odd-chain saturated fatty acid (OCS-FA) with oral activity. Heptadecanoic acid can inhibit cell proliferation and induce Apoptosis. Heptadecanoic acid has antitumor activity. Heptadecanoic acid is associated with a number of diseases, including coronary heart disease, pre-diabetes and type 2 diabetes, and multiple sclerosis.
Environmental Pollutants   Akt   PI3K   Apoptosis  
Pancreatic Cancer   Depression   Pain   Digestive System Inflammation   Cardiovascular Disease   Glucose Metabolism  
3
HY-W004260 Arachidic acid
Arachidic acid is an orally bioavailable membrane fluidity modulator and receptor/ion channel effector. Arachidic acid does not activate arachidonic acid-sensitive K+ channels in rat midbrain and hypothalamic neurons. Arachidic acid alleviates age-related spatial cognitive impairment. Arachidic acid is applicable for research related to age-related spatial cognitive impairment.

Source: Bee Pollen

Endogenous Metabolite  
Neurodegenerative Disease  
3
HY-P10138 human GIP(3-30), amide
Human GIP(3-30), amide is a high affinity antagonist of the human GIP receptor in vitro. Human GIP(3-30), amide has potential anti-obesity and anti-diabetic effects.
Insulin Receptor  
Metabolic or Endocrine Disease  
3
HY-P0120 Dulaglutide
Dulaglutide (LY2189265) is a glucagon-like peptide-1 (GLP-1) receptor agonist. Dulaglutide can be uesd for the research of type 2 diabetes (T2D) .
GCGR  
Metabolic or Endocrine Disease  
3
HY-D0837 Imidazole
Imidazole (Glyoxaline; 1,3-Diaza-2,4-cyclopentadiene) is a heterocyclic aromatic compound. Imidazole bearing molecules have been used as corrosion, acetylcholinesterase (AChEI) and xanthine oxidase (XO) inhibitors, performing biological activities such as antifungal, antituberculosis, anti-inflammatory, antioxidant, and analgesic, amongst many others. Imidazole inhibits the enzymatic conversion of the endoperoxides (PGG2 and PGH2) to thromboxane A2 by platelet microsomes. Imidazole derivatives exhibits inhibition on SARS-CoV-2 3CLPro enzyme, which is promising for research in the field of Alzheimer’s disease, gout, COVID-19 and thrombo-embolic disease.
MOFs   Ser/Thr Protease   Thrombopoietin Receptor  
Cancer   Neurological, Eye or Ear Disease   Inflammation or Immune System Disease   SARS-CoV-2 Infection  
3
HY-P0276 GIP, human
GIP, human, a peptide hormone consisting of 42 amino acids, is a stimulator of glucose-dependent insulin secretion and a weak inhibitor of gastric acid secretion. GIP, human acts as an incretin hormone released from intestinal K cells in response to nutrient ingestion.
Insulin Receptor  
Metabolic or Endocrine Disease  
3
HY-P1624A Teduglutide TFA
Teduglutide TFA is a dipeptidyl peptidase IV resistant glucagon-like peptide 2 (GLP-2) analogue. Teduglutide TFA can activate the expression of nuclear receptor subfamily 4 group a member 1 (NR4a1)/nur77 and intestinal FXR signaling in human hepatic stellate cells, thereby improving liver inflammation and fibrosis in mice with sclerosing cholangitis. Teduglutide TFA can alleviate intestinal dysfunction in mice, improve lung injury, alleviate obesity related neuroinflammation and cell apoptosis.
Nuclear Hormone Receptor 4A/NR4A   FXR  
Inflammation or Immune System Disease  
2
HY-N0546 Ligustroflavone
Ligustroflavone is an orally active flavonoid compound. Ligustroflavone can be extracted from Ligustrum lucidum. Ligustroflavone antagonizes the calcium-sensing receptor (CaSR), inhibits the RIPK1/RIPK3/MLKL pathway, and downregulates TGF-β/Smad signaling. Ligustroflavone regulates calcium metabolism, protects bone tissue, reduces cerebral ischemic injury, and inhibits liver fibrosis. Ligustroflavone can be used in the study of diabetic osteoporosis, ischemic stroke, and liver fibrosis.
CaSR   RIP kinase   Mixed Lineage Kinase   TGF-beta/Smad  
Neurological, Eye or Ear Disease   Inflammation or Immune System Disease   Colorectal Cancer   Prostate Cancer   Cardiovascular Disease   Glucose Metabolism   Obesity   Lung Fibrosis  
2
HY-N2189 Swertisin
Swertisin is an oral adenosine A1 receptor antagonist and an SGLT2 inhibitor. Swertisin has anti-diabetic, antioxidant properties, inhibits HBV, and improves cognitive and memory impairments in mice.
Adenosine Receptor   HBV   SGLT  
Cancer   Inflammation or Immune System Disease   Viral Infection   Glucose Metabolism   Parkinson's Disease   Obesity  
2
HY-P10136A IA9 TFA
IA9 TFA (human TREM-2 182-190 TFA) is a potent, CNS-penetrant TREM-2 inhibitor. IA9 TFA can diminish the release of proinflammatory cytokines and suppress joint inflammation and damage in a Collagen (HY-P5003)-induced arthritis (CIA) mouse model. IA9 TFA can be used for neuroinflammation PET imaging. IA9 TFA can be used for Rheumatoid arthritis (RA) and neuroinflammation research.
TREM receptor  
Rheumatoid Arthritis  
2
HY-P99646 Golocdacimab
Gocdacimab (MEDI6570) is a fully human IgG1 monoclonal antibody inhibitor targeting the lectin-like oxidized low-density lipoprotein receptor LOX-1. By binding to LOX-1 and blocking its function, gocdacimab effectively reduces the level of free soluble LOX-1, thereby inhibiting key pathological processes such as lipid accumulation, foam cell formation, and vascular wall inflammation. Gocdacimab can interfere with atherosclerosis-related mechanisms, and it is used for research on atherosclerosis, and type 2 diabetes mellitus.

Species: Human

LOX-1  
Type 1 Diabetes   Atherosclerosis and Inflammation  
2
HY-101184 T807
T807 a novel tau positron emission tomography (PET) tracer.
Tau Protein  
Viral Infection   SARS-CoV-2 Infection   Alzheimer's Disease  
2
HY-P1624 Teduglutide
Teduglutide (ALX-0600) is an analog of human glucagon like peptide-2 (GLP-2). Teduglutide can activate the expression of nuclear receptor subfamily 4 group a member 1 (NR4a1)/nur77 and intestinal FXR signaling in human hepatic stellate cells, thereby improving liver inflammation and fibrosis in mice with sclerosing cholangitis. Teduglutide can alleviate intestinal dysfunction in mice, improve lung injury, alleviate obesity related neuroinflammation and cell apoptosis.
Nuclear Hormone Receptor 4A/NR4A   FXR  
Inflammation or Immune System Disease  
2
HY-122704A Surfen dihydrochloride
Surfen dihydrochloride is a potent heparan sulfate antagonist. Surfen inhibits FGF2 binding and signal transduction. Surfen binds to glycosaminoglycans and reduces tau hyperphosphorylation. Surfen dihydrochloride inhibits the activity of recombinant uronyl 2-O-sulfotransferase with an IC50 of approximately 2 μM. Surfen dihydrochloride inhibits HSV-1 viral infection. Surfen dihydrochloride inhibits neural differentiation, delays remyelination, and alleviates EAE.
FGFR   HSV   Tau Protein  
Inflammation or Immune System Disease   Lung Cancer   Prostate Cancer   Liver Cancer   Viral Infection   Neurodegenerative Disease  
2
HY-17552 sn-Glycero-3-phosphocholine
sn-Glycero-3-phosphocholine (Choline Alfoscerate) is a precursor in the biosynthesis of brain phospholipids and increases the bioavailability of choline in nervous tissue. sn-Glycero-3-phosphocholine (Choline Alfoscerate) has significant effects on cognitive function with a good safety profile and tolerability, and is effective in the treatment of Alzheimer's disease and dementia.
Cholinesterase (ChE)   Endogenous Metabolite  
Alzheimer's Disease  
2
HY-P10136 IA9
IA9 (human TREM-2 182-190) is a potent, CNS-penetrant TREM-2 inhibitor. IA9 can diminish the release of proinflammatory cytokines and suppress joint inflammation and damage in a Collagen (HY-P5003)-induced arthritis (CIA) mouse model. IA9 can be used for neuroinflammation PET imaging. IA9 can be used for Rheumatoid arthritis (RA) and neuroinflammation research.
TREM receptor  
Rheumatoid Arthritis  
2
HY-10863 Anandamide
Anandamide is an endocannabinoid. Anandamide modulates both neuronal and immune functions through two protein-coupled cannabinoid receptors (CB1 and CB2). Anandamide can activate numerous other receptors like PPARS, TRPV1, and GPR18/GPR55. Anandamide also has potential anti-fungal and anti-inflammatory activities. Anandamide can be used for the research of Alzheimer’s disease (AD) and ulcerative colitis.
Cannabinoid Receptor   PPAR   TRP Channel   GPR55   Fungal   Tau Protein   Endogenous Metabolite  
Infection   Neurological, Eye or Ear Disease   Inflammation or Immune System Disease   Metabolic or Endocrine Disease  
2
HY-N11885 Ferroptosis-IN-1
Ferroptosis-IN-1 is a A. campylantha diterpenes. Ferroptosis-IN-1 inhibits ferroptosis with an EC50 value of 10 μM. Ferroptosis-IN-1 can be used for neuroinflammation diseases research.
Ferroptosis  
Cancer  
1
HY-D0914A Fast green FCF free acid
Fast green FCF free acid is a dye that is acid-resistant. Fast Green FCF free acid inhibits α-synuclein aggregation, as well as Aβ, P2X4 receptor and TLR4/Myd88/NF-κB. Fast Green FCF free acid is widely used as a staining agent like quantitative stain for histones at alkaline pH after acid extraction of DNA, and as a protein stain in electrophoresis. Fast Green FCF free acid improves cognitive impairment, depression, relieves pain allergies, and promotes reproductive function.
α-synuclein  
Neurological, Eye or Ear Disease  
1
HY-P5524 C12-iE-DAP
C12-iE-DAP (Lauroyl-γ-D-glutamyl-meso-diaminopimelic acid) is a highly potent and selective NOD1 agonist, with an EC50 of 0.027 nM in HEK-Blue cells expressing human NOD1. C12-iE-DAP activates the NOD1/RIPK2 signaling pathway and its downstream p38 MAPK and NF-κB, induces the expression of inflammatory mediators such as IL6 and IL8, and exerts synergistic effects with TLR4, Dectin-1 or Mincle signaling. C12-iE-DAP can be used in studies related to vascular inflammation, tumor metastasis and neuroinflammation.
NOD-like Receptor (NLR)   p38 MAPK   NF-κB   Toll-like Receptor (TLR)  
Cancer   Inflammation or Immune System Disease   CNS Infection  
1
HY-P1362A β-Amyloid (42-1), human TFA
β-Amyloid (42-1), human TFA is the inactive form of Amyloid β Peptide (1-42). β-Amyloid (42-1), human TFA is a 42-amino acid peptide which plays a key role in the pathogenesis of Alzheimer disease.
Amyloid-β  
Neurological, Eye or Ear Disease  
1
HY-P5524A C12-iE-DAP hydrochloride
C12-iE-DAP hydrochloride (Lauroyl-γ-D-glutamyl-meso-diaminopimelic acid hydrochloride) is a highly potent and selective NOD1 agonist, with an EC50 of 0.027 nM in HEK-Blue cells expressing human NOD1. C12-iE-DAP hydrochloride activates the NOD1/RIPK2 signaling pathway and its downstream p38 MAPK and NF-κB, induces the expression of inflammatory mediators such as IL6 and IL8, and exerts synergistic effects with TLR4, Dectin-1 or Mincle signaling. C12-iE-DAP hydrochloride can be used in studies related to vascular inflammation, tumor metastasis and neuroinflammation.
NOD-like Receptor (NLR)   p38 MAPK   NF-κB   Toll-like Receptor (TLR)  
Cancer   Inflammation or Immune System Disease   CNS Infection  
1
HY-105066 Davunetide
Davunetide is an eight amino acid snippet derived from activity-dependent neuroprotective protein (ADNP), a neurotrophic factor that exists in the mammalian CNS. Davunetide possesses neuroprotective, neurotrophic and cognitive protective roperties. Davunetide, a microtubule-stabilizing peptide, interacts with and stabilises neuron-specific βIII-tubulin in vitro. Davunetide penetrates the blood-brain barrier and is non-toxic. Davunetide inhibits Aβ aggregation and Aβ-induced neurotoxicity.
Microtubule/Tubulin   Amyloid-β  
Lung Cancer   Glucose Metabolism   Alzheimer's Disease  
1
HY-P99688 Latozinemab
Latozinemab (AL001) is a recombinant human anti-Sortilin monoclonal antibody. Latozinemab effectively binds Sortilin with a high affinity and blocks the interaction between progranulin protein (PGRN) and Sortilin receptor. Latozinemab has the potential for progranulin gene (GRN) mutations causative of Frontotemporal dementia (FTD) (FTD-GRN) research.

Species: Human

Neurotensin Receptor  
Cancer   Neurological, Eye or Ear Disease  
1
HY-100618 Hispidin
Hispidin, a PKC inhibitor and a phenolic compound can be found in Phellinus linteus, has been shown to possess strong anti-oxidant, anti-cancer, anti-diabetic, and anti-dementia properties.

Source: edible mushrooms, Phellinus linteus

PKC   Endogenous Metabolite   Ferroptosis   Reactive Oxygen Species (ROS)   p38 MAPK   JAK   STAT   JNK   Akt   GSK-3   ERK   Keap1-Nrf2  
Lung Cancer   Breast Cancer   Prostate Cancer   Gastric Cancer   Liver Cancer   Leukemia/Lymphoma/Myeloma   Pancreatic Cancer   Ovarian Cancer   Depression   Pain   Digestive System Inflammation   Cardiovascular Disease   Glucose Metabolism   Parkinson's Disease   Obesity   Lung Fibrosis   Rheumatoid Arthritis  
1
HY-W016409 Ethyl 3,4-dihydroxybenzoate
Ethyl 3,4-dihydroxybenzoate (Protocatechuic acid ethyl ester) is an orally effective, blood-brain barrier-permeable, competitive prolyl hydroxylase (PHD) inhibitor that inhibits the hydroxylation modification of hypoxia-inducible factor (HIF) by PHD. Ethyl 3,4-dihydroxybenzoate stabilizes HIF-1α by inhibiting PHD, activates downstream pathways to induce autophagy and apoptosis of tumor cells, and regulates inflammatory responses, inhibits the NF-κB pathway, improves vascular permeability, and promotes osteoblast differentiation. Ethyl 3,4-dihydroxybenzoate has anti-tumor, anti-hypoxic injury, and bone metabolism regulation effects. It can also be used in the research of cardiovascular protection (such as reducing myocardial ischemic damage), bone tissue engineering (promoting osteogenesis/inhibiting osteoclast differentiation), and prevention and treatment of high-altitude cerebral edema.
HIF/HIF Prolyl-Hydroxylase   Reactive Oxygen Species (ROS)   NO Synthase   Autophagy   Apoptosis  
Metabolic or Endocrine Disease  
1
HY-F0001R NADH disodium salt (Standard)
NADH disodium salt (Disodium NADH) Standard is the analytical standard of NADH disodium salt (HY-F0001). This product is intended for research and analytical applications. NADH disodium salt (Disodium NADH) is an orally effective reduced coenzyme. NADH disodium salt plays a role in regenerating electron donors during cellular energy metabolism, including glycolysis, β-oxidation, and the tricarboxylic acid (TCA) cycle. NADH disodium salt regulates calcium homeostasis by promoting the opening of IP3-gated Ca2+ channels and inhibiting Ryanodine receptor, and affects mitochondrial function through direct interaction with VDAC. NADH disodium salt is used in cytoprotective studies related to cerebral ischemic injury, neurodegenerative diseases, aging, and signal transduction.
Reference Standards   Endogenous Metabolite  
Neurodegenerative Disease   Cerebrovascular Disease   Cellular Senescence  
1
HY-113301 Hexacosanoic acid
Hexacosanoic acid is a very long-chain fatty acid. Abnormally elevated levels of Hexacosanoic acid are closely associated with various diseases, such as X-linked adrenoleukodystrophy, adrenomyeloneuropathy, atherosclerosis, and dementia.
Endogenous Metabolite  
Neurological, Eye or Ear Disease   Blood or Cardio-cerebrovascular Disease  
1
HY-W250122 Glutamic acid sodium salt
Glutamic acid sodium salt (Monosodium glutamate) is an orally active food flavor enhancer. Glutamic acid sodium salt causes ROS generation, mitochondrial dysfunction, and Apoptosis. Glutamic acid sodium salt upregulates CHOP, Grp78, and Bcl-2. Glutamic acid sodium salt impairs cognition, induces depressive-like behavior, induces hyperalgesia, and induces obesity and insulin resistance. Glutamic acid sodium salt can be used to study neurotoxicity (e.g., brain damage, cognitive impairment), metabolic disorders (e.g., obesity, insulin resistance), hepatotoxicity, and renal toxicity, as well as pain-related disorders.
Biochemical Assay Reagents   Reactive Oxygen Species (ROS)   Mitochondrial Metabolism   Apoptosis   HSP   Bcl-2 Family  
Neurological, Eye or Ear Disease   Inflammation or Immune System Disease   Metabolic or Endocrine Disease  
1
HY-113080 N-Acetylornithine
N-Acetylornithine is a precursor of ornithine. N-Acetylornithine is associated with type 2 diabetes.
Others  
Glucose Metabolism  
1
HY-111263 NIAD-4
NIAD-4 is a blood-brain barrier permeable fluorophore for optical imaging of amyloid-β (Aβ) in the central nervous system (CNS) for Alzheimer’s disease (AD). NIAD-4 binds to the same Aβ site with the binding affinity (Ki) of 10 nM.
Fluorescent Dye   Amyloid-β  
1
HY-D0914 Fast Green FCF
Fast Green FCF is a sea green triarylmethane food dye, with absorption maximum ranging from 622 to 626 nm. Fast Green FCF inhibits α-synuclein aggregation, as well as Aβ and P2X4 receptor, and TLR4/Myd88/NF-κB. Fast Green FCF is widely used as a staining agent like quantitative stain for histones at alkaline pH after acid extraction of DNA, and as a protein stain in electrophoresis. Fast Green FCF improves cognitive impairment, depression, relieves pain allergies, and promotes reproductive function.
Environmental Pollutants   α-synuclein  
Neurological, Eye or Ear Disease  
1
HY-W041892 Dimethyl itaconate
Dimethyl itaconate induces innate immune memory (trained immunity), and exhibits immunomodulatory property. Dimethyl itaconate inhibits the activation of microglia, reduces the neuroinflammation and synaptic structural damage. Dimethyl itaconate regulates the composition of intestinal flora.
Reactive Oxygen Species (ROS)  
Infection   Neurological, Eye or Ear Disease   Inflammation or Immune System Disease  
1
HY-W042416 N,N-Dimethylacetamide
N,N-Dimethylacetamide (DMAc) is an organic solvent with blood-brain transmissibility and an FDA-approved drug excipient. N, N-dimethylacetamide exerts anti-inflammatory activity by inhibiting the NF-κB signaling pathway. N, N-dimethylacetamide can be used in studies of weight gain caused by a high-fat diet and neuroinflammation in Alzheimer's disease.
NF-κB  
Neurological, Eye or Ear Disease   Inflammation or Immune System Disease   Metabolic or Endocrine Disease  
1
HY-P990110 Lecanemab (Mouse IgG2a)
Lecanemab (Mouse IgG2a) (Mab158) is a monoclonal antibody that targets soluble β-amyloid and has the potential to reduce cognitive decline. The variable region of Lecanemab (Mouse IGG2a) is consistent with that of Lecanemab, while the constant region is of Mouse IgG2a sequence. Lecanemab (Mouse IgG2a) almost abolishes Aβ accumulation in astrocytes and rescues neurons from Aβ-induced cell death. Lecanemab (Mouse IgG2a) holds promise for research in the field of Alzheimer's disease.

Species: Human

Amyloid-β  
Alzheimer's Disease  
1
HY-P7532 Apolipoprotein E/APOE Protein, Mouse (HEK293, His)
Apolipoprotein E/APOE is a key molecule linking lipid metabolism and neurological function. Apolipoprotein E/APOE gene polymorphisms are closely associated with diseases such as Alzheimer’s disease and atherosclerosis by influencing protein structure and function. Apolipoprotein E/APOE Protein, Mouse (HEK293, His) is a recombinant APOE protein expressed in HEK293 cells, with a C-6*His tag.

Species: Mouse; Source: HEK293

1
HY-P701096 Apolipoprotein E/APOE Protein, Rat (His)
Apolipoprotein E/APOE is essential for lipid transport and is integral to the production, transformation and clearance of plasma lipoproteins.It interacts with various particles to favor HDL and binds to receptors such as LDLR and VLDLR to promote cellular uptake.Apolipoprotein E/APOE Protein, Rat (His) is the recombinant rat-derived Apolipoprotein E/APOE protein, expressed by E.coli , with N-6*His labeled tag.

Species: Rat; Source: E. coli

1
HY-144026S 9-PAHSA-d9
9-PAHSA-d9 is the deuterium labeled 9-PAHSA (HY-120657). 9-PAHSA is an orally active endogenous GPR120 agonist (EC50=18 μM). 9-PAHSA significantly inhibits LPS-induced inflammatory responses by blocking the NF-κB pathway. 9-PAHSA induces adipocyte browning, enhances glucose uptake and reduces lipid accumulation, while improving mitochondrial function and the survival rate of steatotic hepatocytes. In terms of neuroprotection, 9-PAHSA regulates the expression of REST and BDNF in the prefrontal cortex of diabetic mice, and effectively prevents spatial working memory deficits and abnormal social behaviors. 9-PAHSA does not directly regulate insulin secretion or improve systemic insulin sensitivity, and possesses specific anti-inflammatory, metabolic regulatory and neuroprotective properties. 9-PAHSA can be used in the research of diabetes-related cognitive impairment, obesity and non-alcoholic fatty liver disease.
CGRP Receptor   NF-κB  
Inflammation or Immune System Disease  
/
HY-10450S5 Dapagliflozin-13C6-1
Dapagliflozin-13C6-1 is 13C labeled Dapagliflozin. Dapagliflozin (BMS-512148), a new type of agent used to treat diabetes mellitus (DM), is a competitive sodium/glucose cotransporter 2 (SGLT2) inhibitor, which results in excretion of glucose into the urine. Dapagliflozin induces HIF1 expression and attenuates renal IR injury.
Isotope-Labeled Compounds   SGLT  
Cancer   Metabolic or Endocrine Disease  
/
HY-P992057 Armanezumab
Armanezumab is a monoclonal antibody that targets and inhibits tau protein, and it specifically binds to the exposed N-terminal domain of pathological tau protein. Armanezumab can be used in relevant studies on Alzheimer's disease, frontotemporal dementia, and Pick's disease.

Species: Human

Tau Protein  
Alzheimer's Disease  
/
HY-15461S1 Ertugliflozin-d9
Ertugliflozin-d9 is deuterated labeled Ertugliflozin (HY-15461). Ertugliflozin (PF-04971729) is a potent, selective and orally active inhibitor of the sodium-dependent glucose cotransporter 2 (SGLT2), with an IC50 of 0.877 nM for h-SGLT2. Has the potential for the treatment of type 2 diabetes mellitus.
SGLT   Isotope-Labeled Compounds  
Metabolic or Endocrine Disease  
/
HY-N10606 Uvagrandol
Uvagrandol potently inhibits α-glucosidase and porcine lipase (IC50: 15.2 μM, 11.2 μM respectively). Uvagrandol can be used in the research of Type 2 diabetes and obesity.
Glycosidase  
Metabolic or Endocrine Disease  
/
HY-158252S Tiagabine-d5 hydrochloride
Tiagabine-d5 (hydrochloride) is deuterium labeled Tiagabine (hydrochloride). Tiagabine hydrochloride (NO050328; NO328; TGB) is an orally active, highly selective, and reversible GAT-1 inhibitor and anticonvulsant that crosses the blood-brain barrier. By blocking the reuptake of GABA in neurons and glial cells, tiagabine increases extracellular GABA levels to enhance inhibitory signal transduction, thereby exerting multiple activities such as anticonvulsant, neuroprotective, and antioxidant effects. Tiagabine hydrochloride exhibits linear pharmacokinetic properties. Although it is metabolized by CYP3A and has a high protein binding rate, it carries a low risk of cognitive impairment. Tiagabine hydrochloride is widely used in research on related diseases including epilepsy (including refractory partial seizures), alcohol withdrawal symptoms, and Huntington's disease.
Isotope-Labeled Compounds   GABA Receptor  
Neurological, Eye or Ear Disease  
/
HY-P10192 Amyloid Bri Protein (1-23)
Amyloid Bri Protein (1-23) (ABri peptide (1-23); ABri23) is a physiological 23-amino-acid peptide released from the C-terminus of the type II transmembrane protein Bri2 (ITM2B, Integral Membrane Protein 2B) following cleavage by the furin protease. Amyloid Bri Protein (1-23) interacts with the extracellular Brichos domain of Bri2 during Bri2 biosynthesis. Amyloid Bri Protein (1-23) interacts with amyloid β peptide (Aβ1-40, thereby inhibiting its aggregation and fibril formation. Amyloid Bri Protein (1-23) can be used in studies related to Alzheimer's disease and familial British dementia.
Amyloid-β  
Alzheimer's Disease  
/
HY-17368S2 Rivastigmine-d3 hydrochloride
Rivastigmine-d3 hydrochloride is deuterated labeled Rivastigmine (HY-17368). Rivastigmine (ENA 713 free base) is an orally active and potent cholinesterase (ChE) inhibitor and inhibits butyrylcholinesterase (BChE) and acetylcholinesteras (AChE) with IC50s of 0.037 μM , 4.15 μM, respectively. Rivastigmine can pass the blood brain barrier (BBB). Rivastigmine is a parasympathomimetic or cholinergic agent used for the research of mild to moderate dementia of the Alzheimer's type and dementia due to Parkinson's disease.
Cholinesterase (ChE)   Isotope-Labeled Compounds  
Neurological, Eye or Ear Disease  
/
HY-10933S CX516-d10
CX516-d10 is the deuterium labeled CX516. CX516 (BDP 12) is an ampakine and acts as an AMPA receptor positive allosteric modulator for the research of Alzheimer's disease, schizophrenia and mild cognitive impairment (MCI).
Isotope-Labeled Compounds   iGluR  
Neurological, Eye or Ear Disease  
/
HY-B1804S1 Tricaprilin-d50
Tricaprilin-d50 (Trioctanoin-d50) is the deuterium labeled Tricaprilin (HY-B1804). Tricaprilin is an orally active and well tolerated ketogenic agent that safely induces ketosis. Tricaprilin restores brain electrical activity and metabolism to help counteract neuroinflammation in migraine. Tricaprilin is promising for research of migraine prevention and Alzheimer’s disease (AD). Tricaprilin is a pure C8 medium chain triglyceride (MCT).
Isotope-Labeled Compounds   Endogenous Metabolite  
Neurological, Eye or Ear Disease   Inflammation or Immune System Disease  
/
HY-10450S3 Dapagliflozin-13C6
Dapagliflozin-13C6 (BMS-512148-13C6) is 13C labeled Dapagliflozin. Dapagliflozin (BMS-512148), a new type of agent used to treat diabetes mellitus (DM), is a competitive sodium/glucose cotransporter 2 (SGLT2) inhibitor, which results in excretion of glucose into the urine. Dapagliflozin induces HIF1 expression and attenuates renal IR injury.
Isotope-Labeled Compounds  
Cancer   Metabolic or Endocrine Disease  
/
HY-P992407 MEDI-4166
MEDI-4166 is an antibody-peptide gene fusion molecule of a PCSK9 antibody and a GLP-1 analog. MEDI-4166 is applicable to research related to type 2 diabetes.

Species: Human

PCSK9   GLP Receptor  
Autoimmune Disease  
/
HY-12879G IWP-4 (GMP)
IWP-4 (GMP) is the GMP-grade form of IWP-4 (HY-12879). IWP-4 is a Wnt inhibitor with an IC50 of 25 nM. IWP-4 specifically inhibits casein kinase 1δ/ε (CK1δ/ε), with an IC50 of 1.06 μM against wild-type CK1δ, 1.02 μM against the CK1δ kinase domain, and 7.07 μM against CK1ε; it shows enhanced inhibitory activity against the M82F CK1δ mutant (IC50 = 0.14 μM). IWP-4 is applicable to research related to cancer, Alzheimer's disease (AD), and heart failure.
Wnt   Casein Kinase  
Cancer   Alzheimer's Disease   Heart Failure  
/
HY-N18020 Saurufuran A
Saurufuran A is a PPARγ agonist with an EC50 of 16.7 μM. Saurufuran A is applicable to research related to type 2 diabetes, inflammatory diseases and certain cancers.
Others  
Cancer   Inflammation or Immune System Disease   Type 2 Diabetes  
/
HY-10451S2 Canagliflozin-d6
Canagliflozin-d6 is the deuterium labeled Canagliflozin. Canagliflozin (JNJ 28431754) is a selective SGLT2 inhibitor with IC50s of 2 nM, 3.7 nM, and 4.4 nM for mSGLT2, rSGLT2, and hSGLT2 in CHOK cells, respectively.
SGLT  
Metabolic or Endocrine Disease  
/
HY-N8414 Dehydrogeijerin
Dehydrogeijerin is an inhibitor of acetylcholinesterase with an IC50 of 9.7 μM. Dehydrogeijerin can be used in study Alzheimer’s disease.
Cholinesterase (ChE)  
Neurological, Eye or Ear Disease  
/
HY-W703629 Acetohexamide-d11
Acetohexamide-d11 is the deuterium labeled Acetohexamide (HY-B0881). Acetohexamide is a first-generation sulfonylurea agent used in research related to type 2 diabetes; it stimulates the pancreas to secrete insulin.Acetohexamide inhibits ATP-sensitive potassium channels in the β cells of the pancreas.
Isotope-Labeled Compounds   Potassium Channel  
Metabolic or Endocrine Disease  
/
HY-W768207 Cytidine-1',2',3',4',5'-13C5
Cytidine-1',2',3',4',5'-13C5 is the 13C-labeled Cytidine (HY-B0158). Cytidine is a pyrimidine nucleoside and acts as a component of RNA. Cytidine is a precursor of uridine. Cytidine controls neuronal-glial glutamate cycling, affecting cerebral phospholipid metabolism, catecholamine synthesis, and mitochondrial function.
Isotope-Labeled Compounds   Endogenous Metabolite   Nucleoside Antimetabolite/Analog  
Neurological, Eye or Ear Disease  
/
HY-P991536 KHK6640
KHK6640 is a humanized anti-amyloid beta oligomer-specific antibody. KHK6640 demonstrates high potency and efficacy for cognitive improvement in several rodent Alzheimer’s models. KHK6640 can be studied in research for neurological diseases such as Alzheimer’s disease.

Species: Human

Amyloid-β  
Neurological, Eye or Ear Disease  
/
HY-Z3935S 3-Epi empagliflozin-d4
3-Epi empagliflozin-d4 is the deuterium labeled 3-Epi empagliflozin.
Isotope-Labeled Compounds  
/
HY-167843 Alborixin
Alborixin is a polycyclic polyether ionophore Antibiotic. Alborixin is isolated from cultures of Streptomyces albus. Alborixin induces Autophagy via PTEN-mediated inhibition of the AKT pathway, thereby clearing Amyloid-β. Alborixin exhibits activity against Gram-positive bacteria and fungi. Alborixin can be used in the research of Alzheimer's disease.

Source: streptomyces scabrisporus

Akt   Autophagy   PTEN   Amyloid-β   Antibiotic   Bacterial   Fungal  
Bacterial Infection   Fungal Infection   Alzheimer's Disease  
/
HY-B0863S5 Glyphosate-13C,15N-1
Glyphosate-13C,15N-1 is the 13C- and 15N-labeled Glyphosate (HY-B0863). Glyphosate, a non-selective systemic biocide with broad-spectrum activity, is an herbicidal derivative of the amino acid glycine. Glyphosate inhibits the enzymatic activity of the 5-endopyruvylshikimate 3-phosphate synthase (EPSPS) in the shikimic acid pathway, preventing the synthesis of the aromatic amino acids tyrosine, phenylalanine, and tryptophan. Glyphosate induces oxidative stress, neuroinflammation, and mitochondrial dysfunction, processes that lead to neuronal death by autophagia, necrosis, or apoptosis, as well as the appearance of behavioral and motor disorders.
Isotope-Labeled Compounds   Necroptosis   Autophagy   Apoptosis  
Neurological, Eye or Ear Disease  
/
HY-N7687 Caulophyllogenin
Caulophyllogenin is a triterpene saponin extracted from M. polimorpha. Caulophyllogenin is a partial PPARγ agonist, with an EC50 of 12.6 μM. Caulophyllogenin can be used for the research of type-2 diabetes, obesity, metabolic syndrome and inflammation.
PPAR  
Inflammation or Immune System Disease   Metabolic or Endocrine Disease  
/
HY-106276 (D-Ala)-Peptide T
(D-Ala)-Peptide T is an octapeptide derived from gp120. (D-Ala)-Peptide T releases chemokines and prevents HIV-1 GP120-induced neuronal death. (D-Ala)-Peptide T can be used in research on infectious and neurological diseases such as AIDS-related dementia.
HIV  
HIV Infection   Alzheimer's Disease  
/
HY-N13380 6′‐O‐Galloylsalidroside
6’-O-Galloylsalidroside is an active component of Rhodiola. 6’-O-Galloylsalidroside is promising for research of Alzheimer’s disease, lung diseases, cerebrovascular disease, diabetes, cardiovascular disease and aging-related diseases.
Others  
Neurological, Eye or Ear Disease   Blood or Cardio-cerebrovascular Disease   Metabolic or Endocrine Disease  
/
HY-N20189 Rosa roxburghii fruit extract
Rosa roxburghii fruit extract is an extract of Rosa roxburghii that can be used in research on type 2 diabetes.
Others  
Glucose Metabolism  
/
HY-W017540S Cyclocreatine-13C3
Cyclocreatine-13C3 is the 13C-labeled Cyclocreatine (HY-W017540). Cyclocreatine, a creatine analogue, acts as a brain-penetrant and potent bioenergetic protective agent by providing high levels of ATP. Cyclocreatine can be phosphorylated and dephosphorylated by creatine kinases. Cyclocreatine suppresses creatine metabolism ameliorating the cognitive, autistic and epileptic phenotype in a mouse model of creatine transporter defciency. Cyclocreatine protects against ischemic injury and enhances cardiac recovery during early reperfusion in dogs and rats. Cyclocreatine decreases plaque-adjacent neuronal dystrophy in TREM2-deficient mice with amyloid-β pathology. Cyclocreatine is proming for research of ischemic heart disease, cardiovascular diseases, Alzheimer’s disease and other neurodegenerative diseases associated with microglial dysfunction, prostate cancer.
Isotope-Labeled Compounds   ATP Synthase  
Cancer   Neurological, Eye or Ear Disease   Blood or Cardio-cerebrovascular Disease   Metabolic or Endocrine Disease  
/
HY-P991376 BIIB076
BIIB076 is a human monoclonal antibody (mAb) targeting PHF-tau. BIIB076 can be used for passive immunity research in Alzheimer's disease (AD).

Species: Human

Tau Protein  
Neurological, Eye or Ear Disease  
/
HY-P1060A LPYFD-NH2 TFA
LPYFD-NH2 TFA, a pentapeptide, exerts some inhibitory effect on the aggregation of Aβ(1-42). LPYFD-NH2 TFA can be used for the research of Alzheimer’s disease.
Amyloid-β  
Neurological, Eye or Ear Disease  
/
HY-D2967 Golgi-NO
Golgi-NO is a Golgi-targeted fluorescent probe for nitric oxide (NO) (Ex/Em: 560 nm/589 nm). Golgi-NO exhibits excellent selectivity for various potential interfering substances. Golgi-NO can be used to study the function of NO within the Golgi apparatus in disease models such as Alzheimer's disease (AD).
Fluorescent Dye  
Alzheimer's Disease  
/
HY-166652S Empagliflozin-d8
Empagliflozin-d8 is the deuterium labeled Empagliflozin. Empagliflozin (BI 107730 is a selective sodium glucose cotransporter-2 (SGLT-2) inhibitor with an IC50 of 3.1 nM for human SGLT-2.
Isotope-Labeled Compounds   SGLT  
Cancer   Metabolic or Endocrine Disease  
/
HY-N7109S3 Erucic acid-d18-1
Erucic acid-d18-1 is the deuterium labeled Erucic acid (HY-N7109). Erucic acid, a monounsaturated fatty acid (MUFA), is isolated from the seed of Raphanus sativus L. Erucic acid can readily cross the blood-brain barrier (BBB), it has been reported to normalize the accumulation of very long-chain fatty acids in the brain. Erucic acid can improve cognitive impairment and be effective against dementia.
Isotope-Labeled Compounds   Endogenous Metabolite   PI3K  
/
HY-P1060 LPYFD-NH2
LPYFD-NH2, a pentapeptide, exerts some inhibitory effect on the aggregation of Aβ(1-42). LPYFD-NH2 can be used for the research of Alzheimer’s disease.
Amyloid-β  
Neurological, Eye or Ear Disease  
/
HY-129131 Chrysin 6-C-arabinoside 8-C-glucoside
Chrysin 6-C-arabinoside 8-C-glucoside is a α±-glucosidase inhibitors which are widely used in the study for type 2 diabetes.
Glycosidase  
Metabolic or Endocrine Disease  
/
HY-14928S1 Lobeglitazone-d4
Lobeglitazone-d4 is deuterium labeled Lobeglitazone. Lobeglitazone is a new type of thiazolidinedione. Lobeglitazone can be used to prevent type 2 diabetes mellitus (T2DM).
Isotope-Labeled Compounds   Others  
Metabolic or Endocrine Disease  
/
HY-187270S [U-15N]-ApoE4
[U-15N]-ApoE4 is the 15N-labeled ApoE4. Apolipoprotein E4 (ApoE4) is a significant genetic risk factor for Alzheimer's disease and is closely linked to cardiovascular diseases-such as atherosclerosis-through its influence on lipid metabolism. This isotope can be used in NMR studies of disease mechanisms and in mass spectrometry analysis.
Isotope-Labeled Compounds  
Atherosclerosis and Inflammation  
/
HY-P11092 TLQP-62 (mouse,rat)
TLQP-62 (mouse,rat) is a secreted C-terminal peptide that can be derived from protein VGF. TLQP-62 activates the BDNF-TrkB signaling pathway, inducing acute, transient phosphorylation of TrkB receptor and downstream CREB (Ser133) phosphorylation. TLQP-62 demonstrates excellent efficacy in promoting long-term fear memory formationin wild-type mice and reversing memory impairment in VGF heterozygous knock-out mice. TLQP-62 can be used for the study of memory-related neurological disorders (e.g., Alzheimer’s disease, frontotemporal dementia).
Endogenous Metabolite  
Neurological, Eye or Ear Disease  
/
HY-B0158S2 Cytidine-13C-1
Cytidine-13C-1 is the 13C labeled Cytidine. Cytidine is a pyrimidine nucleoside and acts as a component of RNA. Cytidine is a precursor of uridine. Cytidine controls neuronal-glial glutamate cycling, affecting cerebral phospholipid metabolism, catecholami
Isotope-Labeled Compounds   Endogenous Metabolite   Nucleoside Antimetabolite/Analog  
Neurological, Eye or Ear Disease  
/
HY-Y0399R L-Norvaline (Standard)
L-Norvaline (Standard) is the analytical standard of L-Norvaline (HY-Y0399). This product is intended for research and analytical applications. L-Norvaline is the inhibitor for arginase, that promotes the production of NO, reduces oxidative stress, improves insulin resistance, and exhibits antioxidant and anti-hyperglycemic effects. L-Norvaline can be used in research of Alzheimer’s disease.
Reference Standards   Amyloid-β   TNF Receptor   Arginase  
/
HY-187251S [U-13C,15N]-hTau-441
[U-13C,15N]-hTau-441 is the 13C- and 15N-labeled hTau-441. Abnormal levels and aggregation of hTau-441 in the brain are considered key factors in the pathogenesis of Alzheimer's disease (AD). This isotope can be used in NMR studies of disease mechanisms and in mass spectrometry analysis.
Isotope-Labeled Compounds  
Neurodegenerative Disease  
/
HY-B0158S3 Cytidine-d2-1
Cytidine-d2-1 is the deuterium labeled Cytidine. Cytidine is a pyrimidine nucleoside and acts as a component of RNA. Cytidine is a precursor of uridine. Cytidine controls neuronal-glial glutamate cycling, affecting cerebral phospholipid metabolism, catech
Isotope-Labeled Compounds   Endogenous Metabolite   Nucleoside Antimetabolite/Analog  
Neurological, Eye or Ear Disease  
/
HY-B0763S1 Ibudilast-d7
Ibudilast-d7 is the deuterium labeled Ibudilast. Ibudilast (KC-404; AV-411; MN-166) is a cyclic AMP phosphodiesterase (PDE) inhibitor. Ibudilast has platelet anti-aggregatory effects. Ibudilast can be used for the research of asthma for its inhibitory effects on tracheal smooth muscle contractility. Ibudilast may be a useful neuroprotective and anti-dementia agent counteracting neurotoxicity in activated microglia.
Isotope-Labeled Compounds   Phosphodiesterase (PDE)  
Cancer   Inflammation or Immune System Disease  
/
HY-W725496 D-Fructose 6-phosphate dipotassium
D-Fructose 6-phosphate dipotassium is an endogenous metabolite in saliva that affects cell growth and autophagy; it can be hydrolyzed by Fructose-1,6-bisphosphatase (FBPase). D-Fructose 6-phosphate dipotassium can be converted into D-glucose 6-phosphate (HY-112537) by the action of phosphoglucose isomerase. D-Fructose 6-phosphate dipotassium is a sugar intermediate in the glycolysis pathway and the pentose phosphate pathway. D-Fructose 6-phosphate dipotassium can be used to study Lewy body dementia.
Endogenous Metabolite  
Neurological, Eye or Ear Disease   Metabolic or Endocrine Disease  
/
HY-P992275 Anti-Nicastrin Antibody (A5226A)
Anti-Nicastrin Antibody (A5226A) is a monoclonal antibody against Nicastrin and an inhibitor of γ-secretase. Anti-Nicastrin Antibody (A5226A) recognizes the fully glycosylated mature presenilin enhancer in the active γ-secretase complex and inhibits its activity via competition for substrate binding. Anti-Nicastrin Antibody (A5226A) abrogates the growth of cancer cells dependent on γ-secretase activity. Anti-Nicastrin Antibody (A5226A) serves as an imaging tool to visualize the endocytic trafficking of active γ-secretase, and also acts as a detection reagent to evaluate the endocytic efficiency of γ-secretase. Anti-Nicastrin Antibody (A5226A) can be used in studies related to non-small cell lung cancer, T-cell acute lymphoblastic leukemia and Alzheimer's disease.

Species: Human

γ-secretase  
Non-Small Cell Lung Cancer   Acute Lymphoblastic Leukemia   Alzheimer's Disease  
/
HY-D3180 CDr20
CDr20 is a fluorescent chemical probe capable of crossing the blood-brain barrier. CDr20 undergoes glucuronidation catalyzed by the UDP-glucuronosyltransferase Ugt1a7c, which triggers a fluorescence turn-on response. CDr20 enables visualization of live microglial cells. CDr20 can be used for research on Alzheimer's disease, stroke, and autism.
Fluorescent Dye  
Cerebrovascular Disease   Alzheimer's Disease  
/
HY-N15659 Crystamidine
Crystamidine is an alkaloid can be isolated from the flower and seed extracts of Erythrina caffra Thunb., Fabaceae. Crystamidine can be studied in research on Alzheimer’s disease.
Biochemical Assay Reagents  
Neurological, Eye or Ear Disease  
/
HY-167153 PNA5
PNA5 is a novel, blood-brain barrier permeable glycosylated angiotensin-(1-7) peptide and MasR agonist. PNA5 inhibits IL-7, increases IL-10. PNA5 inhibits ROS generation, decreases Iba-1 expression. PNA5 exhibits sustained cognitive protective effects. PNA5 rescues blunted cerebral functional hyperemia. PNA5 can be used in the research of inflammation-related brain diseases.
Interleukin Related   Reactive Oxygen Species (ROS)  
Neurological, Eye or Ear Disease   Inflammation or Immune System Disease   Blood or Cardio-cerebrovascular Disease  
/
HY-14894S2 Pragliflozin-13C6
Pragliflozin-13C6 (ASP1941-13C6) is 13C labeled Ipragliflozin. Ipragliflozin (ASP1941) is an orally active and selective SGLT2 inhibitor with IC50s of 7.38 and 1876 nM, 6.73 and 1166 nM, 5.64 and 1380 nM for human SGLT2 and SGLT1, rat SGLT2 and SGLT1, mouse SGLT2 and SGLT1, respectively. Antidiabetic agent.
Isotope-Labeled Compounds   SGLT  
Metabolic or Endocrine Disease  
/
HY-D3215 Lyso-Cu(II)
Lyso-Cu (II) is a lysosome-targeted divalent copper ion probe. Lyso-Cu (II) is applicable to the research of Wilson's disease, Menkes disease and Alzheimer's disease.
Fluorescent Dye  
Alzheimer's Disease  
/
HY-16900G Rolipram (GMP)
Rolipram GMP is Rolipram (HY-16900) produced by using GMP guidelines. GMP small molecules works appropriately as an auxiliary reagent for cell therapy manufacture. Rolipram is a PDE4 inhibitor, with blood-brain barrier permeability, that reverses β-amyloid-induced learning and memory impairment in rats. Rolipram elevates intracellular cAMP and clevels and regulates the cAMP/CREB signaling pathway, thereby alleviating neuroinflammation and apoptotic responses. Rolipram promotes neuronal differentiation of human bone marrow mesenchymal stem cells and inhibits Methamphetamine- and morphine-induced hyperlocomotion in mice. Rolipram also reduces the viability of glioblastoma stem-like cells and enhances Bevacizumab (HY-P9906)-induced cell death. Rolipram inhibits the expression of proinflammatory cytokines and enhances central noradrenergic transmission. Rolipram is mainly used in studies related to various central nervous system diseases including Alzheimer's disease, major depressive disorder, glioblastoma multiforme, and multiple sclerosis.
Phosphodiesterase (PDE)   Epigenetic Reader Domain   Amyloid-β  
Depression   Glioblastoma Multiforme   Alzheimer's Disease   Multiple Sclerosis  
/
HY-N7394 Galbacin
Galbacin ((3S)-Zuonin A), the epimer of (-)-Zuonin A (HY-N7394A), is a AMPK activator. Galbacin can be isolated from Myristica fragrans (nutmeg). Galbacin stimulates AMPK enzyme in differentiated C2C12 cells. Galbacin also has anticancer activity, and inhibits the proliferation of lymphocyte and tumor cells. Galbacin prevents weight gain in diet-induced mice model. Galbacin can be used for metabolic syndrome (including obesity and type-2 diabetes) and caners research.
AMPK  
Metabolic or Endocrine Disease  
/
HY-P11414 Cys-flag peptide
Cys-flag peptide (CDYKDDDDK) is a FLAG tag peptide containing cysteine. Cys-flag peptide has a targeted interaction for protein purification and detection. Cys-flag peptide can be used for the research of neurological disease, such as Alzheimer’s disease.
Others  
/
HY-P3780 Cys-Gly-Lys-Lys-Gly-Amyloid β-Protein (36-42)
Cys-Gly-Lys-Lys-Gly-Amyloid β-Protein (36-42) is the 36-42 fragment of Amyloid β-Protein. β-amyloid, a polypeptide made up of 36-43 amino acids, is the main component of amyloid plaques found in the brains of people with Alzheimer's disease. β-amyloid oligomers (Aβos) plays A key role in the progression of Alzheimer's disease (AD) by inducing neuronal damage and cognitive impairment.
Amyloid-β  
Neurological, Eye or Ear Disease  
/
HY-N13251 Verbena Extract
Verbena Extract is a verbena extract. Verbena Extract is a potential anti-ischemic stroke agent, and its mechanism may be related to IL17A-mediated neuroinflammation regulation..
Others  
Neurological, Eye or Ear Disease  
/
HY-P991249 NI-203
NI-203 is a monoclonal antibody inhibitor that targets amylin. NI-203 is promising for research of type 2 diabetes.

Species: Human

Amylin Receptor  
Metabolic or Endocrine Disease  
/
HY-113301S Hexacosanoic acid-d4
Hexacosanoic acid-d4 is the deuterium labeled Hexacosanoic acid (HY-113301). Hexacosanoic acid is a very long-chain fatty acid. Abnormally elevated levels of Hexacosanoic acid are closely associated with various diseases, such as X-linked adrenoleukodystrophy, adrenomyeloneuropathy, atherosclerosis, and dementia.
Isotope-Labeled Compounds   Endogenous Metabolite  
Neurological, Eye or Ear Disease   Blood or Cardio-cerebrovascular Disease  
/
HY-D2343 PB0822
PB0822 can be used for in vivo PET imaging when labeled with [18F]fluoride. [18F]PB0822 is a PET radioligand. [18F]PB0822 has a cLogP value of 1.54, which is a good predictive index for BBB penetration. [18F]PB0822 can be used for Alzheimer’s Disease research.
Biochemical Assay Reagents  
Neurological, Eye or Ear Disease  
/
HY-N2715 6-Methoxynaringenin
6-Methoxynaringenin is a natural flavonoid that inhibits NO production with an IC50 of 25.8 μM.
NO Synthase  
Inflammation or Immune System Disease  
/
HY-P11677 CPO_Aβ17-21P
CPO_Aβ17-21P is a apoE/Aβ interaction inhibitor with an IC50 of 1.02 nM. CPO_Aβ17-21P significantly inhibits ApoE4-mediated aggregation of Aβ40 and Aβ42. CPO_Aβ17-21P significantly improves cognitive function and comprehensively alleviates Alzheimer's disease (AD)-related pathologies in mouse models. CPO_Aβ17-21P is applicable to the research of AD.
Alzheimer's Disease  
/
HY-B0531S Triflusal-d3
Triflusal-d3 is deuterium labeled Triflusal (HY-B0531). Triflusal is an orally bioavailable, blood-brain barrier-permeable dual Cyclooxygenase-1 (COX-1)/cAMP phosphodiesterase inhibitor. Triflusal inhibits platelet aggregation, NF-κB activation, iNOS activity, and prostaglandin synthesis in ischaemic tissue. Triflusal stimulates neutrophil nitric oxide production, eNOS protein expression, and cNOS activity. Triflusal alleviates cerebral ischemic injury in rats and ameliorates pathological lesions and related gene expression in transgenic Alzheimer’s disease models. Triflusal can be used for the research of thromboembolic/ischemic cardiovascular and cerebrovascular diseases, and Alzheimer’s disease.
Isotope-Labeled Compounds   COX   NF-κB   Phosphodiesterase (PDE)   NO Synthase   Prostaglandin Receptor  
Colorectal Cancer   Prostate Cancer   Pancreatic Cancer   Depression   SARS-CoV-2 Infection   Rheumatoid Arthritis  
/
HY-N1995 Methylswertianin
Methylswertianin is an active constituent in Swertia punicea Hemsl, with anti-diabetic effect. Methylswertianin can abates type-2 diabetes, likely via the improvement of insulin resistance (IR).
Others  
Metabolic or Endocrine Disease  
/
HY-187250S [U-15N]-hTau-441
[U-15N]-hTau-441 is the 15N-labeled hTau-441. Abnormal levels and aggregation of hTau-441 in the brain are considered key factors in the pathogenesis of Alzheimer's disease (AD). This isotope can be used in NMR studies of disease mechanisms and in mass spectrometry analysis.
Isotope-Labeled Compounds  
Neurodegenerative Disease  
/
HY-P1051 β-Amyloid (12-28)
β-Amyloid (12-28) (Amyloid β-Protein (12-28)) is a peptide fragment of β-amyloid protein (β1-42). β1-42, a 42 amino acid protein , is the major component of senile plaque cores. β-Amyloid (12-28) shows aggregation properties. β-Amyloid (12-28) has the potential for Alzheimer’s disease research.
Amyloid-β  
Neurological, Eye or Ear Disease  
/
HY-D3207 DHUCu-1
DHUCu-1 is a lysosome-targeted NIR divalent copper ion probe with high water solubility. DHUCu-1 serves as a tool for investigating the physiological functions of Cu2+ and related diseases, such as Menke syndrome, Wilson's disease, and Alzheimer's disease.
Fluorescent Dye  
Alzheimer's Disease  
/
HY-D3430 PTPA-QM
PTPA-QM is a low-cytotoxicity Aβ protein probe that can be used for live-cell imaging and tissue section staining (Lys. Ex/Em = 385/615 nm). PTPA-QM can intercalate into the β-sheet layered structure of β-amyloid fibrils, form intermolecular interactions with amino acid residues, restrict intramolecular rotation and trigger fluorescence activation for imaging purposes. PTPA-QM is applicable to Alzheimer's disease-related research. Maximum excitation/emission wavelength: 448/605 nm.
Fluorescent Dye   Amyloid-β  
Alzheimer's Disease  
/
HY-17387S1 (-)-Huperzine A-d4 hydrochloride
(-)-Huperzine A-d4 hydrochloride is deuterated labeled (-)-Huperzine A (HY-17387). (-)-Huperzine A (Huperzine A) is an alkaloid isolated from Huperzia serrata, with neuroprotective activity. (-)-Huperzine A is a potent, highly specific, reversible and blood-brain barrier penetrant inhibitor of acetylcholinesterase (AChE), with an IC50 of 82 nM. (-)-Huperzine A also is non-competitive antagonist of N-methyl-D-aspartate glutamate (NMDA) receptor. (-)-Huperzine A is developed for the research of neurodegenerative diseases, including Alzheimer’s disease.
iGluR   Apoptosis   Cholinesterase (ChE)   Isotope-Labeled Compounds  
Neurological, Eye or Ear Disease  
/
HY-N15649 Ostruthol
Ostruthol is a coumarin and a potent inhibitor of AChE. Ostruthol can be studied in research on Alzheimer’s disease.
Cholinesterase (ChE)  
Neurological, Eye or Ear Disease  
/
HY-P992007 PF-06293620
PF-06293620 (RN909) is a monoclonal antibody antagonist of the glucagon receptor. PF-06293620 produces dose-dependent, durable lowering of fasting plasma glucose and reduces HbA1c levels. PF-06293620 can be used for the research of type 2 diabetes mellitus.

Species: Human

GCGR  
Type 2 Diabetes  
/
HY-P992172 ADEL-Y01
ADEL-Y01 is a humanized and parental murine blood-brain barrier-penetrating monoclonal antibody against tau-acK280. ADEL-Y01 specifically recognizes tau-acK280 and its surrounding residues, mediates the neutralization and phagocytosis of acetylated tau aggregates, and interferes with the activity of pathological tau protein. ADEL-Y01 prevents the progression of tauopathies, increases neuronal survival rate, reduces tau-related pathological changes, and improves memory impairment. ADEL-Y01 can be used in research related to Alzheimer's disease and tauopathies.

Species: Human

Tau Protein  
Alzheimer's Disease  
/
HY-B0696AS Tiagabine-d4 hydrochloride
Tiagabine-d4 hydrochloride is deuterated labeled Tiagabine hydrochloride (HY-B0696A). Tiagabine hydrochloride (NO050328; NO328; TGB) is an orally active, highly selective, and reversible GAT-1 inhibitor and anticonvulsant that crosses the blood-brain barrier. By blocking the reuptake of GABA in neurons and glial cells, tiagabine increases extracellular GABA levels to enhance inhibitory signal transduction, thereby exerting multiple activities such as anticonvulsant, neuroprotective, and antioxidant effects. Tiagabine hydrochloride exhibits linear pharmacokinetic properties. Although it is metabolized by CYP3A and has a high protein binding rate, it carries a low risk of cognitive impairment. Tiagabine hydrochloride is widely used in research on related diseases including epilepsy (including refractory partial seizures), alcohol withdrawal symptoms, and Huntington's disease.
Isotope-Labeled Compounds   GABA Receptor  
Neurological, Eye or Ear Disease  
/
HY-P991269 LY2189102
LY2189102 is a humanized monoclonal antibody inhibitor targeting interleukin-1β (IL-1β). LY2189102 is promising for research of type 2 diabetes.

Species: Human

Interleukin Related  
Metabolic or Endocrine Disease  
/
HY-P3388 Utreglutide
Utreglutide is an effective glucagon-like peptide 1 (GLP-1) receptor agonist. Utreglutide can lower blood pressure, blood lipids and body weight, and improve cardiovascular metabolism. Utreglutide can be used for research on type 2 diabetes or non-type 2 diabetes obesity.
GLP Receptor  
Blood or Cardio-cerebrovascular Disease   Metabolic or Endocrine Disease  
/
HY-184832 P021
P021 (Peptide 021) is an orally active, blood-brain barrier penetrant neurotrophic/neurogenic pentapeptide derived from the most active region of ciliary neurotrophic factor (CNTF). P021 competitively inhibits leukemia inhibitory factor (LIF) and promotes BDNF transcription. P021 targets neurogenesis and synaptic plasticity. P021 prevents neurodegeneration, Amyloid-β pathology, tau protein pathology and cognitive deficits, rescues episodic memory impairment and reduces mortality in 3xTg-AD mice. P021 is applicable to the research of Alzheimer's disease.
Amyloid-β   Tau Protein  
Alzheimer's Disease  
/
HY-B0158S4 Cytidine-d1
Cytidine-d is the deuterium labeled Cytidine. Cytidine is a pyrimidine nucleoside and acts as a component of RNA. Cytidine is a precursor of uridine. Cytidine controls neuronal-glial glutamate cycling, affecting cerebral phospholipid metabolism, catechol
Isotope-Labeled Compounds   Endogenous Metabolite   Nucleoside Antimetabolite/Analog  
Neurological, Eye or Ear Disease  
/
HY-P991435 CEP-37248
CEP-37248 is a human monoclonal antibody (mAb) targeting IL-12. CEP-37248 can be used in Alzheimer's disease research.

Species: Human

Interleukin Related  
Neurological, Eye or Ear Disease  
/
HY-NP009A α-Lactalbumin calcium depleted
α-Lactalbumin (calcium depleted) is the calcium-depleted form of α-Lactalbumin (HY-NP009). α-Lactalbumin (calcium depleted) can be used for protein-membrane interaction research. α-Lactalbumin (calcium depleted) can be used for Alzheimer's disease research.
Biochemical Assay Reagents  
Neurological, Eye or Ear Disease  
/
HY-B0158S8 Cytidine-d13
Cytidine-d13 (Cytosine β-D-riboside-d13) is deuterium labeled Cytidine (HY-B0158). Cytidine is a pyrimidine nucleoside and acts as a component of RNA. Cytidine is a precursor of uridine. Cytidine controls neuronal-glial glutamate cycling, affecting cerebral phospholipid metabolism, catecholamine synthesis, and mitochondrial function.
Nucleoside Antimetabolite/Analog   Endogenous Metabolite   Isotope-Labeled Compounds  
Neurological, Eye or Ear Disease  
/
HY-17355BS Dexpramipexole-d3 dihydrochloride
Dexpramipexole-d3 ((R)-Pramipexole-d3) dihydrochloride is the deuterium labeled Dexpramipexole. Dexpramipexole ((R)-Pramipexole) dihydrochloride is an orally active, blood-brain barrier permeable mitochondrial protective agent. Dexpramipexole dihydrochloride upregulates the expression of Parkin, PINK1, GPX4 and FSP1; binds to mitochondrial F1/Fo-ATP synthase; blocks the Nav1.8 sodium channel; and inhibits the activation of the NLRP3 inflammasome. Dexpramipexole dihydrochloride induces mitophagy, inhibits ferroptosis, pyroptosis, apoptosis, neuroinflammation and eosinophilopoiesis; maintains mitochondrial function and redox homeostasis; reduces reactive oxygen species production; and decreases myocardial infarct size. Dexpramipexole dihydrochloride is applicable to studies on eosinophilic asthma, myocardial ischemia/reperfusion injury, sepsis-associated encephalopathy, analgesia, and more.
Reactive Oxygen Species (ROS)   Isotope-Labeled Compounds   Glutathione Peroxidase   Ferroptosis   Apoptosis   Sodium Channel   Mitophagy   Autophagy   ATP Synthase   NOD-like Receptor (NLR)   PINK1/Parkin  
Neurological, Eye or Ear Disease   Inflammation or Immune System Disease   Blood or Cardio-cerebrovascular Disease  
/
HY-105066R Davunetide (Standard)
Davunetide (Standard) is the analytical standard of Davunetide (HY-105066). This product is intended for research and analytical applications. Davunetide is an eight amino acid snippet derived from activity-dependent neuroprotective protein (ADNP), a neurotrophic factor that exists in the mammalian CNS. Davunetide possesses neuroprotective, neurotrophic and cognitive protective roperties. Davunetide, a microtubule-stabilizing peptide, interacts with and stabilises neuron-specific βIII-tubulin in vitro. Davunetide penetrates the blood-brain barrier and is non-toxic. Davunetide inhibits Aβ aggregation and Aβ-induced neurotoxicity.
Reference Standards   Microtubule/Tubulin   Amyloid-β  
/
HY-B0696S1 Tiagabine-d4
Tiagabine-d4 (NO050328-d4) is deuterium labeled Tiagabine. Tiagabine (NO050328; NO328; TGB) is an orally active, highly selective, and reversible GAT-1 inhibitor and anticonvulsant that crosses the blood-brain barrier. By blocking the reuptake of GABA in neurons and glial cells, tiagabine increases extracellular GABA levels to enhance inhibitory signal transduction, thereby exerting multiple activities such as anticonvulsant, neuroprotective, and antioxidant effects. Tiagabine exhibits linear pharmacokinetic properties. Although it is metabolized by CYP3A and has a high protein binding rate, it carries a low risk of cognitive impairment. Tiagabine is widely used in research on related diseases including epilepsy (including refractory partial seizures), alcohol withdrawal symptoms, and Huntington's disease.
Isotope-Labeled Compounds   GABA Receptor  
Neurological, Eye or Ear Disease  
/
HY-17368S1 (Rac)-Rivastigmine-d6
(Rac)-Rivastigmine-d6 is a labelled racemic Rivastigmine. Rivastigmine (ENA 713 free base) is an orally active and potent cholinesterase (ChE) inhibitor and inhibits butyrylcholinesterase (BChE) and acetylcholinesteras (AChE) with IC50s of 0.037 μM , 4.15 μM, respectively. Rivastigmine can pass the blood brain barrier (BBB). Rivastigmine is a parasympathomimetic or cholinergic agent used for the research of mild to moderate dementia of the Alzheimer's type and dementia due to Parkinson's disease.
Isotope-Labeled Compounds   Cholinesterase (ChE)  
Neurological, Eye or Ear Disease  
/
HY-N8372 Nalanthalide
Nalanthalide is a voltage-gated potassium channel Kv1.3 blocker (IC50=3.9 µM) and a potential immunosuppressant. Nalanthalide can be used for research on inflammatory immune diseases, such as neuroinflammation.

Source: Nalanthamala sp.

Potassium Channel  
Inflammation or Immune System Disease  
/
HY-B0130AS Perindopril-d3 erbumine
Perindopril-d3 (erbumine) is deuterated labeled Perindopril (erbumine) (HY-B0130A). Perindopril erbumine is an angiotensin-converting enzyme inhibitor. Perindopril erbumine modulates NF-κB and STAT3 signaling and inhibits glial activation and neuroinflammation. Perindopril erbumine can be used for the research of Chronic Kidney Disease and high blood pressure.
NF-κB   Angiotensin-converting Enzyme (ACE)   Sirtuin   STAT   Isotope-Labeled Compounds  
Cancer   Blood or Cardio-cerebrovascular Disease  
/
HY-P0014AS Liraglutide-d8 tetraTFA
Liraglutide-d8 tetraTFA is deuterium labeled Liraglutide (HY-P0014). Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used for the study of type 2 diabetes mellitus.
Isotope-Labeled Compounds   GLP Receptor  
Metabolic or Endocrine Disease  
/
HY-N15450 Undulatine
Undulatine is a potent AChE inhibitor with an IC50 of 7.4 μM. Undulatine is able to cross the BBB by passive permeation and can be used in the study of Alzheimer’s disease.
Cholinesterase (ChE)  
Neurological, Eye or Ear Disease  
/
HY-14258R Escitalopram (Standard)
Escitalopram (Standard) is the analytical standard of Escitalopram. This product is intended for research and analytical applications. Escitalopram ((S)-Citalopram), the S-enantiomer of racemic Citalopram, is a selective serotonin reuptake inhibitor (SSRI) with a Ki of 0.89 nM. Escitalopram has ～30 fold higher binding affinity than its R(-)-enantiomer and shows selectivity over both dopamine transporter (DAT) and norepinephrine transporter (NET). Escitalopram is an antidepressant for the research of major depression.
Serotonin Transporter   Reference Standards  
Cancer   Neurological, Eye or Ear Disease  
/
HY-P1624S Teduglutide-Ala(13C3,15N) sodium
Teduglutide-Ala(13C3,15N) (ALX-0600-Ala(13C3,15N)) sodium is the 13C- and 15N-labeled Teduglutide (HY-P1624). Teduglutide (ALX-0600) is an analog of human glucagon like peptide-2 (GLP-2). Teduglutide can activate the expression of nuclear receptor subfamily 4 group a member 1 (NR4a1)/nur77 and intestinal FXR signaling in human hepatic stellate cells, thereby improving liver inflammation and fibrosis in mice with sclerosing cholangitis. Teduglutide can alleviate intestinal dysfunction in mice, improve lung injury, alleviate obesity related neuroinflammation and cell apoptosis.
Isotope-Labeled Compounds   FXR   Nuclear Hormone Receptor 4A/NR4A  
/
HY-15461S Ertugliflozin-d5
Ertugliflozin-d5 is the deuterium labeled Ertugliflozin. Ertugliflozin (PF-04971729) is a potent, selective and orally active inhibitor of the sodium-dependent glucose cotransporter 2 (SGLT2), with an IC50 of 0.877 nM for h-SGLT2. Has the potential for the treatment of type 2 diabetes mellitus.
SGLT  
Metabolic or Endocrine Disease  
/
HY-N15565 Theleganbanin C
Theleganbanin C is a p-terphenyl derivative found in the Thelephora ganbajun. Theleganbanin C is promising for research of neurodegenerative diseases .

Source: Thelephora ganbajun Zang

Drug Derivative  
Neurological, Eye or Ear Disease   Inflammation or Immune System Disease  
/
HY-120657S 9-PAHSA-d4
9-PAHSA-d4 is the deuterium labeled 9-PAHSA. 9-PAHSA is an orally active endogenous GPR120 agonist (EC50=18 μM). 9-PAHSA significantly inhibits LPS-induced inflammatory responses by blocking the NF-κB pathway. 9-PAHSA induces adipocyte browning, enhances glucose uptake and reduces lipid accumulation, while improving mitochondrial function and the survival rate of steatotic hepatocytes. In terms of neuroprotection, 9-PAHSA regulates the expression of REST and BDNF in the prefrontal cortex of diabetic mice, and effectively prevents spatial working memory deficits and abnormal social behaviors. 9-PAHSA does not directly regulate insulin secretion or improve systemic insulin sensitivity, and possesses specific anti-inflammatory, metabolic regulatory and neuroprotective properties. 9-PAHSA can be used in the research of diabetes-related cognitive impairment, obesity and non-alcoholic fatty liver disease.
Isotope-Labeled Compounds   CGRP Receptor   NF-κB  
/
HY-B0763S Ibudilast-d3
Ibudilast-d3 (KC-404-d3) is the deuterium labeled Ibudilast. Ibudilast (KC-404) is a cyclic AMP phosphodiesterase (PDE) inhibitor. Ibudilast has platelet anti-aggregatory effects. Ibudilast can be used for the research of asthma for its inhibitory effects on tracheal smooth muscle contractility. Ibudilast may be a useful neuroprotective and anti-dementia agent counteracting neurotoxicity in activated microglia.
Isotope-Labeled Compounds   Phosphodiesterase (PDE)  
Cancer   Inflammation or Immune System Disease  
/
HY-107203S Propentofylline-d6
Propentofylline-d6 (HWA 285-d6) is the deuterium labeled Propentofylline. Propentofylline is an orally active and brain-penetrant phosphodiesterase inhibitor. Propentofylline blocks adenosine reuptake and prevents cyclic nucleotide degradation. Propentofylline can be used for the research of primary degenerative (Alzheimer's) dementia, vascular dementia, cerebral ischemia, acute stroke, and learning and memory disorders.
Isotope-Labeled Compounds   Phosphodiesterase (PDE)   Adenosine Receptor  
Colorectal Cancer   Alzheimer's Disease  
/
HY-W654336 (S)-Rivastigmine-d4
(S)-Rivastigmine-d4 is deuterium labeled Rivastigmine. Rivastigmine (ENA 713 free base) is an orally active and potent cholinesterase (ChE) inhibitor and inhibits butyrylcholinesterase (BChE) and acetylcholinesteras (AChE) with IC50s of 0.037 μM , 4.15 μM, respectively. Rivastigmine can pass the blood brain barrier (BBB). Rivastigmine is a parasympathomimetic or cholinergic agent used for the research of mild to moderate dementia of the Alzheimer's type and dementia due to Parkinson's disease.
Isotope-Labeled Compounds   Cholinesterase (ChE)  
Neurological, Eye or Ear Disease  
/
HY-B0696S Tiagabine-d6
Tiagabine-d6 (NO050328-d6) is deuterium labeled Tiagabine. Tiagabine (NO050328; NO328; TGB) is an orally active, highly selective, and reversible GAT-1 inhibitor and anticonvulsant that crosses the blood-brain barrier. By blocking the reuptake of GABA in neurons and glial cells, tiagabine increases extracellular GABA levels to enhance inhibitory signal transduction, thereby exerting multiple activities such as anticonvulsant, neuroprotective, and antioxidant effects. Tiagabine exhibits linear pharmacokinetic properties. Although it is metabolized by CYP3A and has a high protein binding rate, it carries a low risk of cognitive impairment. Tiagabine is widely used in research on related diseases including epilepsy (including refractory partial seizures), alcohol withdrawal symptoms, and Huntington's disease.
Isotope-Labeled Compounds   GABA Receptor  
Neurological, Eye or Ear Disease  
/
HY-N7109B Erucic acid sodium
Erucic acid sodium, a monounsaturated fatty acid (MUFA), is isolated from the seed of Raphanus sativus L. Erucic acid sodium can readily cross the blood-brain barrier (BBB), it has been reported to normalize the accumulation of very long-chain fatty acids in the brain. Erucic acid sodium can improve cognitive impairment and be effective against dementia.
PI3K   Endogenous Metabolite  
Neurological, Eye or Ear Disease  
/
HY-120657S1 9-PAHSA-d31
9-PAHSA-d31 is the deuterium labeled 9-PAHSA. 9-PAHSA is an orally active endogenous GPR120 agonist (EC50=18 μM). 9-PAHSA significantly inhibits LPS-induced inflammatory responses by blocking the NF-κB pathway. 9-PAHSA induces adipocyte browning, enhances glucose uptake and reduces lipid accumulation, while improving mitochondrial function and the survival rate of steatotic hepatocytes. In terms of neuroprotection, 9-PAHSA regulates the expression of REST and BDNF in the prefrontal cortex of diabetic mice, and effectively prevents spatial working memory deficits and abnormal social behaviors. 9-PAHSA does not directly regulate insulin secretion or improve systemic insulin sensitivity, and possesses specific anti-inflammatory, metabolic regulatory and neuroprotective properties. 9-PAHSA can be used in the research of diabetes-related cognitive impairment, obesity and non-alcoholic fatty liver disease.
Isotope-Labeled Compounds   CGRP Receptor   NF-κB  
/
HY-135164 Lonchocarpic acid
Lonchocarpic acid has an anti-inflammatory mechanism of lonchocarpine in LPS- or poly(I:C)-induced neuroinflammation.
Insecticide  
Inflammation or Immune System Disease  
/
HY-15409S1 Empagliflozin-13C6
Empagliflozin-13C6 (BI 10773-13C6) is 13C labeled Empagliflozin. Empagliflozin (BI 107730 is a selective sodium glucose cotransporter-2 (SGLT-2) inhibitor with an IC50 of 3.1 nM for human SGLT-2.
Isotope-Labeled Compounds  
Cancer   Metabolic or Endocrine Disease  
/
HY-10450S2 Dapagliflozin-d4
Dapagliflozin-d4 (BMS-512148-d4) is deuterium labeled Dapagliflozin. Dapagliflozin (BMS-512148), a new type of agent used to treat diabetes mellitus (DM), is a competitive sodium/glucose cotransporter 2 (SGLT2) inhibitor, which results in excretion of glucose into the urine. Dapagliflozin induces HIF1 expression and attenuates renal IR injury.
Isotope-Labeled Compounds   SGLT  
Cancer   Metabolic or Endocrine Disease  
/
HY-W654335 Rivastigmine-d4 tartrate
Rivastigmine-d4 (tartrate) is deuterium labeled Rivastigmine (tartrate). Rivastigmine tartrate (ENA 713; SDZ-ENA 713) is an orally active and potent cholinesterase (ChE) inhibitor and inhibits butyrylcholinesterase (BChE) and acetylcholinesteras (AChE) with IC50s of 0.037 μM, 4.15 μM, respectively. Rivastigmine tartrate can pass the blood brain barrier (BBB). Rivastigmine tartrate is a parasympathomimetic or cholinergic agent used for the research of mild to moderate dementia of the Alzheimer's type and dementia due to Parkinson's disease.
Isotope-Labeled Compounds   Cholinesterase (ChE)  
Neurological, Eye or Ear Disease  
/
HY-15409S2 Empagliflozin-d6
Empagliflozin-d6 (BI 10773-d6) is deuterium labeled Empagliflozin. Empagliflozin (BI 107730 is a selective sodium glucose cotransporter-2 (SGLT-2) inhibitor with an IC50 of 3.1 nM for human SGLT-2.
Isotope-Labeled Compounds   SGLT  
Cancer   Metabolic or Endocrine Disease  
/
HY-122607S DPA-714-d10
DPA-714-d10 is the deuterium labeled DPA-714 (HY-122607). DPA-714 is a high affinity translocator protein (TSPO) ligand (Ki=7 nM), which is designed with a fluorine atom in its structure, allowing labelling with fluorine -18 and in vivo imaging using positron emission tomography. 18FDPA-714 successfully evaluates for the specific imaging of inflammation in various models of neuroinflammation and in a brain tumor model.
Isotope-Labeled Compounds   TSPO   Mitochondrial Metabolism  
Cancer   Inflammation or Immune System Disease  
/
HY-N2195R Nootkatone (Standard)
Nootkatone (Standard) is the analytical standard of Nootkatone. This product is intended for research and analytical applications. Nootkatone, a neuroprotective agent from Vitis vinifera, has antioxidant and anti-inflammatory effects[1]. Nootkatone improves cognitive impairment in lipopolysaccharide-induced mouse model of Alzheimer's disease[2].
Reference Standards   Interleukin Related   TNF Receptor  
Neurological, Eye or Ear Disease  
/
HY-W010202 Dihydrolinalool
Dihydrolinalool, Dihydrolinalool is commonly used as a flavor ingredient in various products, including food, beverages, and perfumes, and it can also be used as a base material for the synthesis of various organic compounds, including pharmaceuticals and agrochemicals. In addition, due to Dihydrolinalool's low toxicity and Biodegradability, which has been studied for its potential use as a bio-based solvent, has also been studied for its potential antioxidant and anti-inflammatory properties, which may make it useful in the study of various diseases, including cancer and Alzheimer's disease. Alzheimer's disease.
Environmental Pollutants  
Cancer   Neurodegenerative Disease  
/
HY-B1018AS Phenelzine-d5 sulfate
Phenelzine-d5 sulfate is the deuterium labeled Phenelzine sulfate (HY-B1018A). Phenelzine sulfate, an antidepressant agent, is an irreversible and orally active monoamine oxidase (MAO-A and MAO-B) inhibitor. Phenelzine sulfate inhibits GABA transaminase and primary amine oxidase (PrAO), and sequester reactive aldehydes. Phenelzine sulfate also inhibits LSD1 (Ki: 5.6 μM) and suppresses oxidative stress and lipogenesis. Phenelzine sulfate elevates neurotransmitters (serotonin, norepinephrine, dopamine). Phenelzine sulfate is studied in neurological, metabolic and cancer diseases for depression and anxiety disorders, stroke, spinal cord injury, traumatic brain injury, multiple sclerosis, Parkinson’s disease, Alzheimer’s disease, inflammatory pain, obesity and prostate cancer.
Isotope-Labeled Compounds   Monoamine Oxidase   GABA Receptor   Histone Demethylase  
Cancer   Neurological, Eye or Ear Disease   Inflammation or Immune System Disease   Blood or Cardio-cerebrovascular Disease   Metabolic or Endocrine Disease  
/
HY-D0404 Direct red 254
Direct Red 254 is a bisazo dye for textile applications. Direct Red 254 can be used for amyloid tissue staining in basic research on neurodegenerative diseases (e.g., Alzheimer's disease).
Fluorescent Dye  
Alzheimer's Disease  
/
HY-W747676 Glyphosate-13C
Glyphosate-13C is the 13C-labeled Glyphosate (HY-B0863). Glyphosate, a non-selective systemic biocide with broad-spectrum activity, is an herbicidal derivative of the amino acid glycine. Glyphosate inhibits the enzymatic activity of the 5-endopyruvylshikimate 3-phosphate synthase (EPSPS) in the shikimic acid pathway, preventing the synthesis of the aromatic amino acids tyrosine, phenylalanine, and tryptophan. Glyphosate induces oxidative stress, neuroinflammation, and mitochondrial dysfunction, processes that lead to neuronal death by autophagia, necrosis, or apoptosis, as well as the appearance of behavioral and motor disorders.
Isotope-Labeled Compounds   Necroptosis   Autophagy   Apoptosis  
Neurological, Eye or Ear Disease  
/
HY-P991711 Povovetug
Povovetug is a humanized IgG1κ chimeric monoclonal antibody inhibitor targeting NGF/bNGF. Povovetug has a significant analgesic activity. Povovetug can be used for central neuroinflammation like chronic radicular pain research.

Species: Human

Trk Receptor  
Neurological, Eye or Ear Disease   Inflammation or Immune System Disease  
/
HY-P4704 α-Synuclein (61-95) (human)
α-Synuclein (61-95) (human) is the hydrophobic core region of α-synuclein, and induces neuronal cell death. α-Synuclein (61-95) (human) can be used for research of neurodegenerative diseases, including Alzheimer’s disease (AD) and Parkinson’s disease (PD).
α-synuclein  
Neurological, Eye or Ear Disease  
/
HY-113301S1 Hexacosanoic acid-d4-1
Hexacosanoic acid-d4-11 is the deuterium labeled Hexacosanoic acid (HY-113301). Hexacosanoic acid is a very long-chain fatty acid. Abnormally elevated levels of Hexacosanoic acid are closely associated with various diseases, such as X-linked adrenoleukodystrophy, adrenomyeloneuropathy, atherosclerosis, and dementia.
Isotope-Labeled Compounds   Endogenous Metabolite  
Neurological, Eye or Ear Disease   Blood or Cardio-cerebrovascular Disease  
/
HY-P1624S1 Teduglutide-Leu(13C6,15N) sodium
Teduglutide-Leu(13C6,15N) (ALX-0600-Leu(13C6,15N)) sodium is the 13C- and 15N-labeled Teduglutide (HY-P1624). Teduglutide (ALX-0600) is an analog of human glucagon like peptide-2 (GLP-2). Teduglutide can activate the expression of nuclear receptor subfamily 4 group a member 1 (NR4a1)/nur77 and intestinal FXR signaling in human hepatic stellate cells, thereby improving liver inflammation and fibrosis in mice with sclerosing cholangitis. Teduglutide can alleviate intestinal dysfunction in mice, improve lung injury, alleviate obesity related neuroinflammation and cell apoptosis.
Isotope-Labeled Compounds   FXR   Nuclear Hormone Receptor 4A/NR4A  
/
HY-B1804S Tricaprilin-13C3
Tricaprilin-13C3 (Trioctanoin-13C3) is a 13C-labeled Tricaprilin (HY-B1804). Tricaprilin is an orally active and well tolerated ketogenic agent that safely induces ketosis. Tricaprilin restores brain electrical activity and metabolism to help counteract neuroinflammation in migraine. Tricaprilin is promising for research of migraine prevention and Alzheimer’s disease (AD). Tricaprilin is a pure C8 medium chain triglyceride (MCT).
Isotope-Labeled Compounds   Endogenous Metabolite  
Neurological, Eye or Ear Disease   Inflammation or Immune System Disease  
/
HY-P990990 Efsubaglutide alfa
Efsubaglutide alfa is a long-acting humanised GLP-1 receptor agonist. Efsubaglutide alfa binds specifically to the GLP-1 receptor, enhancing glucose-dependent insulin secretion, suppressing glucagon release, and promoting β-cell proliferation and increased β-cell mass. Efsubaglutide alfa improves glucose tolerance, increases pancreatic insulin content, and enhances β-cell secretory responses in isolated human islets. Efsubaglutide alfa reduces liver steatosis, lowers NAFLD Activity Scores, improves perisinusoidal collagen features, reduces serum ALT and AST levels, improves fasting glucose and triglyceride levels, and reduces body weight, liver weight and liver-to-body weight ratio. Efsubaglutide alfa can be used for the research of type 2 diabetes. Efsubaglutide alfa can be used for the research of metabolic dysfunction-associated steatohepatitis.

Species: Human

GLP Receptor  
Digestive System Disease   Digestive System Inflammation   Type 2 Diabetes  
/
HY-W770410 9-PAHSA-13C4
9-PAHSA-13C4 is 13C-labeled 9-PAHSA. 9-PAHSAis an orally active endogenous GPR120 agonist (EC50=18 μM). 9-PAHSAsignificantly inhibits LPS-induced inflammatory responses by blocking the NF-κB pathway. 9-PAHSAinduces adipocyte browning, enhances glucose uptake and reduces lipid accumulation, while improving mitochondrial function and the survival rate of steatotic hepatocytes. In terms of neuroprotection, 9-PAHSAregulates the expression of REST and BDNF in the prefrontal cortex of diabetic mice, and effectively prevents spatial working memory deficits and abnormal social behaviors. 9-PAHSAdoes not directly regulate insulin secretion or improve systemic insulin sensitivity, and possesses specific anti-inflammatory, metabolic regulatory and neuroprotective properties. 9-PAHSAcan be used in the research of diabetes-related cognitive impairment, obesity and non-alcoholic fatty liver disease.
Isotope-Labeled Compounds   CGRP Receptor   NF-κB  
/
HY-B0158S5 Cytidine-13C9,15N3
Cytidine-13C9,15N3 is the 13C and 15N labeled Cytidine. Cytidine is a pyrimidine nucleoside and acts as a component of RNA. Cytidine is a precursor of uridine. Cytidine controls neuronal-glial glutamate cycling, affecting cerebral phospholipid metabolism, catecholamine synthesis, and mitochondrial function.
Nucleoside Antimetabolite/Analog   Endogenous Metabolite  
Neurological, Eye or Ear Disease  
/
HY-142117S1 6-Sulfatoxymelatonin-d4
6-Sulfatoxymelatonin-d4 is the deuterated-labeled 6-Sulfatoxymelatonin. 6-Sulfatoxymelatonin is a metabolite of Melatonin (HY-B0075) and serves as a detection marker for Melatonin. 6-Sulfatoxymelatonin shows a decreasing trend with increasing age, and its urinary excretion is closely correlated with plasma Melatonin levels, which can reflect changes in the secretion phase of melatonin. 6-Sulfatoxymelatonin is associated with reduced risks of diabetic retinopathy and coronary heart disease, and can act as a biomarker for microvascular and macrovascular complications of type 2 diabetes mellitus. 6-Sulfatoxymelatonin can be used in studies related to type 2 diabetes mellitus and coronary heart disease.
Isotope-Labeled Compounds   Drug Metabolite  
Type 2 Diabetes  
/
HY-B0158S1 Cytidine-13C
Cytidine-13C is the 13C labeled Cytidine. Cytidine is a pyrimidine nucleoside and acts as a component of RNA. Cytidine is a precursor of uridine. Cytidine controls neuronal-glial glutamate cycling, affecting cerebral phospholipid metabolism, catecholamine
Isotope-Labeled Compounds   Endogenous Metabolite   Nucleoside Antimetabolite/Analog  
Neurological, Eye or Ear Disease  
/
HY-B1804S2 Tricaprilin-d15
Tricaprilin-d15 (Trioctanoin-d15) is the deuterium labeled Tricaprilin (HY-B1804). Tricaprilin is an orally active and well tolerated ketogenic agent that safely induces ketosis. Tricaprilin restores brain electrical activity and metabolism to help counteract neuroinflammation in migraine. Tricaprilin is promising for research of migraine prevention and Alzheimer’s disease (AD). Tricaprilin is a pure C8 medium chain triglyceride (MCT).
Isotope-Labeled Compounds   Endogenous Metabolite  
Neurological, Eye or Ear Disease   Inflammation or Immune System Disease  
/
HY-B0254S Glipizide-d11
Glipizide-d11 is the deuterium labeled Glipizide. Glipizide (CP 2872; K 4024)?a potent, orally active and sulfonylurea class anti-diabetic agent and can be used for type 2?diabetes mellitus research but not type 1. Glipizide acts by partially blocking ATP-sensitive potassium?(KATP) channels among β cells of pancreatic islets of Langerhans.
Isotope-Labeled Compounds   Potassium Channel  
Metabolic or Endocrine Disease  
/
HY-P3588 N-Acetyl semax amidate
N-Acetyl semax amidate is a derivative of Semax (HY-P1146) (Met-Glu-His-Phe-Pro-Gly-Pro) obtained via N-terminal acetylation and C-terminal amidation, and it exhibits nootropic and neuroprotective activities. N-Acetyl semax amidate exerts neuroprotective effects by upregulating the expression of BDNF and NGF, inhibiting neuronal apoptosis, alleviating oxidative stress, and reducing glutamate excitotoxicity. N-Acetyl semax amidate can be used in research related to central nervous system diseases such as ischemic stroke, cognitive impairment, and neurodegenerative diseases.
Biochemical Assay Reagents  
Neurodegenerative Disease   Ischemic Stroke  
/
HY-Y0399S L-Norvaline-d5
L-Norvaline-d5 is the deuterium labeled L-Norvaline. L-Norvaline is the inhibitor for arginase, that promotes the production of NO, reduces oxidative stress, improves insulin resistance, and exhibits antioxidant and anti-hyperglycemic effects. L-Norvaline can be used in research of Alzheimer’s disease.
Isotope-Labeled Compounds   Amyloid-β   TNF Receptor   Arginase  
Neurological, Eye or Ear Disease   Metabolic or Endocrine Disease  
/
HY-W039760 Choline iodide
2-Hydroxy-N,N,N-trimethylethan-1-aminium iodide, also known as choline iodide, is a quaternary ammonium salt commonly used in organic synthesis and biochemical research. It is a water-soluble compound derived from choline, an essential nutrient found in many foods. Choline iodide has been used as a source of choline groups in various chemical reactions and in microbiology as a selective agent for isolating bacteria. In addition, its potential role in cognitive impairment and liver disease has also been studied.
Biochemical Assay Reagents  
/
HY-P0014S2 Liraglutide-13C6,15N TFA
Liraglutide-13C6,15 TFA is the 13C and 15N labeledLiraglutide(HY-P0014). Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used for the study of type 2 diabetes mellitus.
Isotope-Labeled Compounds  
/
HY-P991174 Anti-TREM2 Antibody (AL2p-58)
Anti-TREM2 Antibody (AL2p-58) is a humanized IgG1 monoclonal antibody targeting TREM2. Anti-TREM2 Antibody (AL2p-58) can be used for the research of neuroinflammation. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001).

Species: Human

TREM receptor  
Inflammation or Immune System Disease  
/
HY-50682S Azeliragon-d9
Azeliragon-d9 (TTP488-d9) is the deuterium labeled Azeliragon (HY-50682). Azeliragon (TTP488) is an orally bioavailable inhibitor of the receptor for advanced glycation end products (RAGE) in development as a potential treatment to slow disease progression with mild Alzheimer’s disease (AD). Azeliragon also can cross the blood-brain barrier (BBB).
Isotope-Labeled Compounds   Amyloid-β  
Neurological, Eye or Ear Disease   Metabolic or Endocrine Disease  
/
HY-N0142R Phloretin (Standard)
Phloretin (Standard) is the analytical standard of Phloretin. This product is intended for research and analytical applications. Phloretin (NSC 407292; RJC 02792) is a flavonoid extracted from Malus pumila Mill., has anti-inflammatory activities. Phloridzin is a specific, competitive and orally active inhibitor of sodium/glucose cotransporters in the intestine (SGLT1) and kidney (SGLT2). Phloretin inhibits Yeast-made GLUT1 as well as Human erythrocyte GLUT1 with IC50values of 49 μM and 61 μM, respectively.Phloretin has the potential for the treatment of rheumatoid arthritis (RA) and allergic airway inflammation.
Reference Standards   SGLT   Endogenous Metabolite   GLUT  
Cancer   Metabolic or Endocrine Disease  
/
HY-P1047 β-Sheet Breaker Peptide iAβ5
β-Sheet Breaker Peptide iAβ5 is an effective brain amyloid-β (Abeta) degrader. Abeta deposits are associated with Alzheimer's disease (AD), and the related toxicity arises from its β-sheet conformation and aggregation. β-Sheet Breaker Peptide iAβ5 can repeatedly induce the degradation of fibrillary amyloid deposits in vivo. Therefore, β-Sheet Breaker Peptide iAβ5 can prevent and/or reverse neuronal contraction caused by Abeta and reduce the range of interleukin IL-1beta positive microglial-like cells around Abeta deposits. β-Sheet Breaker Peptide iAβ5 can reduce the size and/or number of brain amyloid plaques in AD. β-Sheet Breaker Peptide iAβ5 is labeled with a hydrophobic benzyl alcohol (HBA) tag and shows a bright blue color under acidic conditions, which can be used for quantitative determination.
Amyloid-β  
Neurological, Eye or Ear Disease  
/
HY-D1443 BSB
BSB is a Congo red-derived fluorescent probe. BSB binds not only to extracellular amyloid β protein, but also many intracellular lesions composed of abnormal tau and synuclein proteins. BSB acts as a prototype imaging agent for Alzheimer's disease.
Amyloid-β  
/
HY-B0158S Cytidine-d2
Cytidine-d2 is the deuterium labeled Cytidine. Cytidine is a pyrimidine nucleoside and acts as a component of RNA. Cytidine is a precursor of uridine. Cytidine controls neuronal-glial glutamate cycling, affecting cerebral phospholipid metabolism, catecholamine synthesis, and mitochondrial function.
Nucleoside Antimetabolite/Analog   Endogenous Metabolite  
Neurological, Eye or Ear Disease  
/
HY-10451S Canagliflozin-d4
Canagliflozin-d4 (JNJ 28431754-d4) is a deuterium labeled Canagliflozin. Canagliflozin is a selective SGLT2 inhibitor.
SGLT  
Cancer   Metabolic or Endocrine Disease  
/
HY-P5311 Albiglutide
Albiglutide is a long acting GLP-1 receptor agonist. Albiglutide is a recombinant fusion protein consisting of two copies of a 30-amino-acid sequence of modified human GLP-1 (fragment 7-36), modified with a glycine substituted for the naturally occurring alanine at position 8 in order to augment resistance to DPP-4. Albiglutide can be used for research of Type 2 diabetes.

Species: Human

GLP Receptor  
Type 2 Diabetes  
/
HY-B0158S6 Cytidine-15N3
Cytidine-15N3 is the 15N labeled Cytidine. Cytidine is a pyrimidine nucleoside and acts as a component of RNA. Cytidine is a precursor of uridine. Cytidine controls neuronal-glial glutamate cycling, affecting cerebral phospholipid metabolism, catecholamine synthesis, and mitochondrial function.
Nucleoside Antimetabolite/Analog   Endogenous Metabolite  
Neurological, Eye or Ear Disease  
/
HY-P10887 Pegevongitide
Pegevongitide (AV-001) is a Tie2 agonist. Pegevongitide resists the increased endothelial cell permeability induced by SARS-CoV-2 infection. Pegevongitide activates the angiogenin (angiogenin)/Tie2 signaling pathway. Pegevongitide reduces perivascular space dilation and upregulates perivascular Aquaporin-4 expression. Pegevongitide decreases the expression of TNF-α, PAI-1, CXCL9 and P-selectin, improves white matter integrity, enhances cognitive function and exerts neuroprotective effects. Pegevongitide improves white matter integrity in middle-aged rats with vascular dementia induced by multiple microinfarctions. Pegevongitide can be used in related research on diseases such as COVID-19 and vascular dementia.
Tie   ANGPTL   SARS-CoV   Aquaporin   TNF Receptor   PAI-1   CXCR   P-selectin  
Neurological, Eye or Ear Disease   Blood or Cardio-cerebrovascular Disease   SARS-CoV-2 Infection  
/
HY-N0505 Rosiridin
Rosiridin inhibits MAO A and MAO B with potential beneficial effect in depression and senile dementia. Rosiridin shows an inhibition of 83.8% against MAO B at 10 μM (pIC50=5.38).
Monoamine Oxidase  
Depression   Parkinson's Disease  
/
HY-N4268 Tenuifoliside B
Tenuifoliside B, a component isolated from Polygalae Radix, inhibits potassium cyanide (KCN)-induced hypoxia and scopolamine-induced memory impairment. Tenuifoliside B shows potential cognitive improvement and cerebral protective effects. Tenuifoliside B has potential to become an anti-AD lead compound.
Others  
Neurological, Eye or Ear Disease  
/
HY-W067445 N-(4-Formylphenyl)acetamide
N-(4-Formylphenyl) acetamide (4-Acetamidobenzaldehyde) is an organic ligand bearing aldehyde and acetamide functional groups. N-(4-Formylphenyl) acetamide can be used to functionalize Fe3O4@SiO2 nanoparticles for selective fluorescence quenching detection of Hg2+. N-(4-Formylphenyl) acetamide serves as a precursor for the synthesis of benzimidazole, benzothiazole and Schiff base derivatives, which exhibit antioxidant, AChE/BChE inhibitory and DNA-binding activities. N-(4-Formylphenyl) acetamide can be applied in studies related to Alzheimer's disease.
Biochemical Assay Reagents   Drug Intermediate  
Alzheimer's Disease  
/
HY-N1479 Polygalic acid
Polygalic acid is a polyphenolic acid with neuroprotective effects, and also an inhibitor of African swine fever virus polymerase (AsfvPolX), with an IC50 value of 5.05 μM. Polygalic acid alleviates neuroinflammation by regulating cholinergic activity, and its fecal level decreases in diseased mice. Polygalic acid can be used in research related to painful diabetic peripheral neuropathy complicated with cognitive impairment and African swine fever.
Cholinesterase (ChE)   DNA/RNA Synthesis  
Neurological, Eye or Ear Disease   Viral Infection   Glucose Metabolism  
/
HY-NP203 High density lipoprotein (human)
High density lipoprotein (human) (HDL (human)) is a human-derived high-density lipoprotein. High density lipoprotein can cross the blood-brain barrier, and partially acts on endothelial nitric oxide synthase (eNOS) by activating surface receptors such as SR-B1 and S1P3R, as well as intracellular signaling cascades involving Akt, PI3K and MAPK, thereby inducing the production of NO in endothelial cells. High density lipoprotein (human) can be used in research related to type 2 diabetes, Alzheimer's disease, cancer and atherosclerosis.
Apolipoprotein   NO Synthase   LPL Receptor   Akt   PI3K   p38 MAPK  
Cancer   Alzheimer's Disease   Atherosclerosis and Inflammation   Type 2 Diabetes  
/
HY-34408 6-Methoxy-1-tetralone
6-Methoxy-1-tetralone is a tetralone derivative and core structure for synthesis of acetylcholinesterase and butyrylcholinesterase inhibitors. 6-Methoxy-1-tetralone can be used for the research of alzheimer’s disease.
Drug Isomer   Cholinesterase (ChE)  
Alzheimer's Disease  
/
HY-P10956 Colulintide
Colulintide (LY3541105) is an amylin-calcitonin dual receptor agonist with Amylin as its scaffold. Colulintide is applicable to research related to type 2 diabetes and obesity.
Amylin Receptor   CGRP Receptor  
Type 2 Diabetes   Obesity  
/
HY-10450S Dapagliflozin-d5
Dapagliflozin-d5 is a deuterium labeled Dapagliflozin (HY-10450). Dapagliflozin is a competitive SGLT2 inhibitor.
Isotope-Labeled Compounds   SGLT  
Cancer   Metabolic or Endocrine Disease  
/
HY-P991670 Abdakibart
Abdakibart (AVTX-009) is a humanized IgG4 monoclonal antibody inhibitor targeting IL-1β. Abdakibart is applicable to research on inflammatory diseases such as type 2 diabetes.

Species: Human

Interleukin Related  
Inflammation or Immune System Disease   Type 2 Diabetes  
/
HY-NP192 Sericin
Sericin is an orally active globular protein produced by silkworm cocoons. Sericin inhibits the expression of COX2, iNOS, TLR4, MAPK and NF-κB; reduces the levels of IL-18, IL-1 and CCL2; antagonizes the activity of AChE; and downregulates the expression of Bcl-2. Sericin enhances the PI3K/AKT-mediated insulin signaling pathway. Sericin inhibits the activity of tyrosinase (Tyrosinase), scavenges ROS, chelates metal ions, and increases the levels of antioxidant enzymes. Sericin induces apoptosis and arrests the cell cycle. Sericin exhibits antibacterial, moisturizing, cardioprotective and anticoagulant properties. Sericin can be used in research related to type 2 diabetes, hyperlipidemia, obesity, Alzheimer's disease, colon cancer, peripheral nerve injury and ischemic myocardial infarction.
Reactive Oxygen Species (ROS)   Bacterial   COX   NO Synthase   Toll-like Receptor (TLR)   p38 MAPK   NF-κB   Interleukin Related   Cholinesterase (ChE)   Bcl-2 Family   Tyrosinase   PI3K   Akt  
Cancer   Infection   Neurological, Eye or Ear Disease   Inflammation or Immune System Disease   Metabolic or Endocrine Disease  
/
HY-P10557 DAG peptide
DAG peptide is a cyclic peptide. DAG peptide selectively recognizes a subset of astrocytes that are activated in Alzheimer's disease (AD) starting at an early stage of the disease. DAG peptide can be used as a tool to enhance the delivery of therapeutics and imaging agents to sites of vascular changes and astrogliosis in diseases associated with neuroinflammation.
Biochemical Assay Reagents  
Neurological, Eye or Ear Disease  
/
HY-113228R Isocitric acid (Standard)
Isocitric acid (Standard) is the analytical standard of Isocitric acid (HY-113228). This product is intended for research and analytical applications. Isocitric acid is an endogenous metabolite present in Saliva and Cellular_Cytoplasm that can be used for the research of Alzheimer's Disease, Lewy Body Dementia and Anoxia.
Reference Standards   Endogenous Metabolite  
Neurological, Eye or Ear Disease  
/
HY-P991373 APNmAb005
APNmAb005 is a human monoclonal antibody (mAb) targeting MAPT/Tau/PHF-tau. APNmAb005 blocks tau seeding in vitro and rescues neuronal loss in rTG4510 mice. APNmAb005 can be used in Alzheimer’s disease (AD) research.

Species: Human

Tau Protein  
Neurological, Eye or Ear Disease  
/
HY-113080R N-Acetylornithine (Standard)
N-Acetylornithine (Standard) is an analytical standard for N-Acetylornithine. This product is intended for research and analytical applications. N-Acetylornithine is a precursor of ornithine. N-Acetylornithine is associated with type 2 diabetes.
Reference Standards   Endogenous Metabolite   Biochemical Assay Reagents  
Metabolic or Endocrine Disease  
/
HY-P10959A Macupatide acetate
Macupatide acetate is a glucose-dependent insulinotropic polypeptide (GIP) receptor agonist. Macupatide acetate improves insulin secretion responses and insulin sensitivity.Macupatide acetate can be used for the research of type 2 diabetes.
Insulin Receptor  
Metabolic or Endocrine Disease  
/
HY-W009411 Dansyl hydrazine
Dansyl hydrazine is a carbohydrate-specific fluorescent dye (Ex/Em = 340 nm/525 nm). Dansyl hydrazine undergoes a condensation reaction with aldehyde groups generated by periodate oxidation on carbohydrate-containing structures to form fluorescent hydrazone compounds. Dansyl hydrazine selectively stains polysaccharides in formalin-fixed, paraffin-embedded human post-mortem brain tissues, revealing detailed structural features. Dansyl hydrazine is applicable to research related to Alzheimer's disease, Lafora disease, and polyglucosan body disease.
Fluorescent Dye  
/
HY-15409S Empagliflozin-d4
Empagliflozin-d4 is deuterium labeled Empagliflozin. Empagliflozin (BI 107730 is a selective sodium glucose cotransporter-2 (SGLT-2) inhibitor with an IC50 of 3.1 nM for human SGLT-2.
SGLT  
Metabolic or Endocrine Disease  
/
HY-N7699C D-Pentamannuronic acid
D-Pentamannuronic acid, an alginate oligomer, is produced by marine brown algae and by a limited range of Gram negative bacteria. D-Pentamannuronic acid can be used for the research of pain and vascular dementia.

Source: marine brown algae and a limited range of Gram negative bacteria

Bacterial  
Neurological, Eye or Ear Disease   Bacterial Infection  
/
HY-15209S Repaglinide-d5
Repaglinide-d5 is deuterium labeled Repaglinide. Repaglinide is an insulin secretagogue for the treatment of type-2 diabetes mellitus.
Isotope-Labeled Compounds   Potassium Channel  
Metabolic or Endocrine Disease  
/
HY-B0158S7 Cytidine-13C9
Cytidine-13C9 (Cytosine β-D-riboside-13C9) is 13C labeled Cytidine (HY-B0158). Cytidine is a pyrimidine nucleoside and acts as a component of RNA. Cytidine is a precursor of uridine. Cytidine controls neuronal-glial glutamate cycling, affecting cerebral phospholipid metabolism, catecholamine synthesis, and mitochondrial function.
Nucleoside Antimetabolite/Analog   Endogenous Metabolite   Isotope-Labeled Compounds  
Neurological, Eye or Ear Disease  
/
HY-P1707A Tau protein (592-597), human TFA
Tau protein (592-597), human TFA is a peptide fragment of human Tau protein. The dysfunction of Tau protein is involved in neurodegeneration and dementia.
Tau Protein  
Neurodegenerative Disease  
/
HY-P991734 VHB937
VHB937 is a potent and selective TREM2 agonist, a human monoclonal antibody, with sub-nanomolar affinity. VHB937 enhances TREM2 surface expression and downstream signaling, such as Syk phosphorylation and calcium mobilization. VHB937 exhibits robust neuroprotective effects in vivo, significantly reducing pathology and pro-inflammatory markers across a broad range of animal models of neuroinflammation and neurodegeneration. VHB937 can be used for neurodegenerative diseases research.

Species: Human

TREM receptor   Syk   Calcium Channel  
Neurological, Eye or Ear Disease   Inflammation or Immune System Disease  
/
HY-N0698 Crocin II
Crocin II is an inhibitor targeting α-synuclein aggregation, with a IC50 of 0.541 μM and a EC50 of 3.63 μM. Crocin II inhibits α-synuclein aggregation and dissociates pre-formed α-synuclein fibrils. Crocin II possesses antioxidant, anticancer and antidepressant activities. Crocin II is applicable to research related to neurological disorders such as Parkinson's disease, dementia with Lewy bodies and multiple system atrophy, as well as cancers.
Endogenous Metabolite   α-synuclein  
Cancer   Parkinson's Disease  
/
HY-W004284S Heptadecanoic acid-d3
Heptadecanoic acid-d3 is the deuterium labeled Heptadecanoic acid. Heptadecanoic acid is an odd chain saturated fatty acid (OCS-FA). Heptadecanoic acid is associated with several diseases, including the incidence of coronary heart disease, prediabetes and type 2 diabetes as well as multiple sclerosis.
Isotope-Labeled Compounds   Endogenous Metabolite  
Cancer   Blood or Cardio-cerebrovascular Disease   Metabolic or Endocrine Disease  
/
HY-P990781 Suciraslimab
Suciraslimab (SM03) is an anti-human CD22 monoclonal antibody. Suciraslimab inhibits NLRP3 and ASC signaling. Suciraslimab suppresses cytokine (IL-1β, IL-12, IL-23) secretion and α4 integrin expression. Suciraslimab improves working memory and neuroinflammation. Suciraslimab isotype control product: Human IgG1 kappa, Isotype Control (HY-P99001).

Species: Human

CD22   NOD-like Receptor (NLR)   Interleukin Related   Integrin  
Neurological, Eye or Ear Disease   Inflammation or Immune System Disease  
/
HY-P99959 Unasnemab
Unasnemab (MT-3921) is a humanised IgG1 monoclonal antibody that binds to repulsive guidance molecule A (RGMa). Unasnemab improves locomotor function and promotes neuroregeneration. Unasnemab exerts ameliorative effects on hippocampal neurogenesis impairment and cognitive decline in db/db mice, Streptozotocin (STZ) (HY-13753)-induced type 1 diabetic and bilateral common carotid artery stenosis (BCAS)-induced mice. Unasnemab can be used for the research of spinal cord injury, diabetes-induced neurological impairments.

Species: Human

TGF-β Receptor  
Neurological, Eye or Ear Disease  
/
HY-W004284S1 Heptadecanoic acid-d33
Heptadecanoic acid-d33 is the deuterium labeled Heptadecanoic acid. Heptadecanoic acid is an odd chain saturated fatty acid (OCS-FA). Heptadecanoic acid is associated with several diseases, including the incidence of coronary heart disease, prediabetes and type 2 diabetes as well as multiple sclerosis.
Endogenous Metabolite  
Cancer   Blood or Cardio-cerebrovascular Disease   Metabolic or Endocrine Disease  
/
HY-P99648 Gosuranemab
Gosuranemab (BMS-986168; IPN007; BIIB092) is a humanised IgG4 anti-tau monoclonal antibody. Gosuranemab neutralizes the extracellular tau protein, inhibiting the spread and aggregation of pathological tau protein. Gosuranemab can be used for the research of progressive supranuclear palsy and early Alzheimer’s disease.

Species: Human

Tau Protein  
Neurological, Eye or Ear Disease  
/
HY-B0158R Cytidine (Standard)
Cytidine (Standard) is the analytical standard of Cytidine. This product is intended for research and analytical applications. Cytidine is a pyrimidine nucleoside and acts as a component of RNA. Cytidine is a precursor of uridine. Cytidine controls neuronal-glial glutamate cycling, affecting cerebral phospholipid metabolism, catecholamine synthesis, and mitochondrial function. In Vivo:Cytidine decreases glutamate/glutamine levels and induces earlier improvement of depressive symptoms.
Reference Standards   Nucleoside Antimetabolite/Analog   Endogenous Metabolite  
Neurological, Eye or Ear Disease  
/
HY-W134326 Polydextrose
Polydextrose is an orally active prebiotic. Polydextrose promotes the growth of Pediococcus pentosaceus ATCC 43200. Polydextrose reduces cholesterol and synergistically lowers blood sugar with Sitagliptin (HY-13749). Currently, it is mainly used in the research of diseases such as hyperlipidemia, type 2 diabetes, and postoperative iron deficiency anemia.
Bacterial  
Infection   Blood or Cardio-cerebrovascular Disease   Metabolic or Endocrine Disease  
/
HY-W250120 Konjac glucomannan (Viscosity≥15000mPa.s)
Konjac glucomannan (Viscosity≥15000mPa.s) is an orally active acetylated (1-4)-β-D-glucomannan with multiple biological activities including anti-diabetic, anti-obesity, anti-inflammatory effects, as well as film-forming and gelling properties. Konjac glucomannan (Viscosity≥15000mPa.s) forms a defensive coating on the intestinal surface, reducing levels of blood glucose, cholesterol, triglycerides and blood pressure; it is specifically degraded by colonic β-mannanase produced by human colonic bacteria. Konjac glucomannan (Viscosity≥15000mPa.s) can be used as a food additive, dietary supplement and excipient for oral colon-targeted drug delivery systems. Konjac glucomannan (Viscosity≥15000mPa.s) is applicable to research related to various diseases such as type 2 diabetes, obesity, atopic dermatitis and metabolic syndrome, as well as research in fields including biotechnology, pharmaceuticals and tissue engineering.
Biochemical Assay Reagents   Drug Intermediate  
Atopic Dermatitis   Type 2 Diabetes   Obesity  
/
HY-P4704A α-Synuclein (61-95) (human) TFA
α-Synuclein (61-95) (human) TFA is the hydrophobic core region of α-synuclein, and induces neuronal cell death. α-Synuclein (61-95) (human) TFA can be used for research of neurodegenerative diseases, including Alzheimer’s disease (AD) and Parkinson’s disease (PD).
α-synuclein  
Neurological, Eye or Ear Disease  
/
HY-P0014S1 Liraglutide-13C5,15N tetraTFA
Liraglutide-13C6,15 tetraTFA is the 13C and 15N labeled Liraglutide (HY-P0014). Liraglutide is a glucagon-like peptide-1 (GLP-1) receptor agonist used for the study of type 2 diabetes mellitus.
Isotope-Labeled Compounds   GCGR   GLP Receptor  
/
HY-148123 Glycerophospholipids, cephalins
Glycerophospholipids and cephalins are a class of phospholipid compounds and important components of neural membranes. Glycerophospholipids and cephalins are hydrolysis substrates of phospholipase (such as PLA2, PLC, and PLD). After complete hydrolysis, they produce 1 mol of glycerol, phosphate, ethanolamine, and 2 mol of fatty acids, respectively. Glycerophospholipids and cephalins can maintain membrane structure, fluidity, and ion permeability, and serve as precursors of second messengers such as arachidonic acid and diacylglycerol. Glycerophospholipids and cephalins can regulate signal transduction, cell apoptosis, and membrane transport, and are used in the study of neurodegenerative diseases (such as Alzheimer's disease).
Biochemical Assay Reagents  
Neurological, Eye or Ear Disease  
/
HY-14536A Methylene blue (purity≥70%)
Methylene blue (purity≥70%) is a guanylyl cyclase (sGC), monoamine oxidase A (MAO-A) and NO synthase (NOS) inhibitor. Methylene blue (purity≥70%) is a vasopressor and is often used as a dye in several medical procedures. Methylene blue (purity≥70%) through the nitric oxide syntase/guanylate cyclase signalling pathway to reduce prepulse inhibition. Methylene blue (purity≥70%) is a REDOX cycling compound and able to cross the blood-brain barrier. Methylene blue (purity≥70%) is a Tau aggregation inhibitor. Methylene blue reduces cerebral edema, attenuated microglial activation and reduced neuroinflammation.
Environmental Pollutants   Microtubule/Tubulin   Guanylate Cyclase   Monoamine Oxidase   NO Synthase  
Cancer   Infection   Neurological, Eye or Ear Disease  
/
HY-P0165 Taspoglutide
Taspoglutide is a long-acting glucagon-like peptide 1 (GLP-1) receptor agonist developed for treatment of type 2 diabetes, with an EC50 value of 0.06 nM.
GCGR  
Metabolic or Endocrine Disease  
/
HY-B1804 Tricaprilin
Tricaprilin (Trioctanoin) is an orally active and well tolerated ketogenic agent that safely induces ketosis. Tricaprilin restores brain electrical activity and metabolism to help counteract neuroinflammation in migraine. Tricaprilin is promising for research of migraine prevention and Alzheimer’s disease (AD). Tricaprilin is a pure C8 medium chain triglyceride (MCT).
Endogenous Metabolite  
Inflammation or Immune System Disease   Alzheimer's Disease  
/
HY-P99164 Zagotenemab
Zagotenemab (LY3303560) is a humanized anti-tau antibody that selectively binds and neutralises tau deposits in the brain. Zagotenemab can be used in Alzheimer's disease research.

Species: Human

Tau Protein  
Alzheimer's Disease  
/
HY-77642 4-(Methylsulfonyl)phenylboronic acid
4-(Methylsulfonyl)phenylboronic acid is an intermediate. 4-(Methylsulfonyl)phenylboronic acid can be used to synthesize GPR119 agonists via Suzuki coupling reaction. 4-(Methylsulfonyl)phenylboronic acid can be used in the research of type 2 diabetes.
Biochemical Assay Reagents   Drug Intermediate  
Metabolic or Endocrine Disease  
/
HY-P99614 Fazpilodemab
Fazpilodemab (BFKB8488A) is a humanized bispecific IgG1 antibody that selectively targets and activates fibroblast growth factor receptor 1c (FGFR1c) and Klothoβ. Fazpilodemab can be used for the research of type 2 diabetes mellitus (T2DM) or nonalcoholic fatty liver disease (NAFLD).

Species: Human

FGFR  
Metabolic or Endocrine Disease  
/
HY-N0507 Rosavin
Rosavin, an orally bioactive phenylpropanoid from Rhodiola rosea L. (RRL), is an adaptogen that enhances the body’s response to environmental stress. Rosavin significantly influences bone tissue metabolism by inhibiting osteoclastogenesis and promoting osteoblast differentiation, also impacts various diseases, demonstrating antidepressant, adaptogenic, and anxiolytic effects in mouse models. Additionally, Rosavin improves survival, reducing intestinal damage in irradiated rats and Ischemia-reperfusion(I/R)-induced cerebral injury in vivo by regulating inflammation and oxidative stress, making it a promising candidate for research in radiation-induced intestinal injury, I/R-induced cerebral injury and osteoporosis.
TNF Receptor   Interleukin Related  
Digestive System Disease   Prostate Cancer   Depression   Digestive System Inflammation   Parkinson's Disease   Lung Fibrosis   Rheumatoid Arthritis  
/
HY-P10227 Xelafaslatide
Xelafaslatide (ONL-1204) is a Fas receptor antagonist. Xelafaslatide blocks the Fas receptor signaling pathway and inhibits downstream apoptosis and inflammatory pathways. Xelafaslatide suppresses neuroinflammation and microglial activation in glaucoma models, protects retinal ganglion cells and prevents axonal degeneration. Xelafaslatide is applicable to relevant research on glaucoma.
Fatty Acid Synthase (FASN)   Apoptosis   Interleukin Related   Toll-like Receptor (TLR)   NOD-like Receptor (NLR)   Caspase  
Glaucoma  
/
HY-P99317 Solanezumab
Solanezumab (LY-2062430) is a humanized monoclonal IgG1 antibody directed against the mid-domain of the amyloid-β (Aβ) peptide. Solanezumab binds to the mid-domain of monomeric amyloid-beta to slow brain amyloid accumulation. Solanezumab can be used for the research of Alzheimer’s disease.

Species: Human

Amyloid-β  
Alzheimer's Disease  
/
HY-N12060 Ginkgo biloba extract
Ginkgo biloba extract is a natural product that can be isolated from Ginkgo biloba leaves. Ginkgo biloba extract alleviates oxidative stress-induced neuronal apoptosis (Apoptosis) by stabilizing mitochondrial function, regulating Bcl-2 family proteins and inhibiting caspase activation. Ginkgo biloba extract alleviates testicular injury by upregulating SKP2 and inhibiting Beclin1-independent autophagy (Autophagy). Ginkgo biloba extract alleviates various types of neuronal damage in animal models. Ginkgo biloba extract reduces behavioral sensitization in rats. Ginkgo biloba extract counteracts Aβ-induced neurotoxicity by blocking a series of Aβ-triggered events, including glucose uptake, ROS accumulation, AKT activation, mitochondrial dysfunction, JNK and ERK 1/2 pathways, and apoptosis, and also interferes with the formation of Aβ oligomers. Ginkgo biloba extract is applicable to research related to cerebral hypoperfusion, testicular injury, Alzheimer's disease, Parkinson's disease, multi-infarct dementia, stroke, traumatic brain injury and amyotrophic lateral sclerosis.
Bcl-2 Family   Caspase   Apoptosis   Autophagy   Reactive Oxygen Species (ROS)   Akt   JNK   ERK  
Blood or Cardio-cerebrovascular Disease   Alzheimer's Disease   Parkinson's Disease   Amyotrophic Lateral Sclerosis  
/
HY-P10959 Macupatide
Macupatide is a glucose-dependent insulinotropic polypeptide (GIP) receptor agonist. Macupatide improves insulin secretion responses and insulin sensitivity.Macupatide can be used for the research of type 2 diabetes.
Insulin Receptor  
Type 2 Diabetes  
/
HY-P1160 Bay 55-9837
Bay 55-9837 is a potent and highly selective agonist of VPAC2, with a Kd of 0.65 nM. Bay 55-9837 may be a useful therapy for the research of type 2 diabetes.
GCGR  
Metabolic or Endocrine Disease  
/
HY-109555 Insulin glulisine
Insulin glulisine (HMR 1964) is a rapid-acting insulin analog whose pharmacokinetic and pharmacodynamic properties mimic physiological insulin secretion in humans, with a rapid onset of action. Insulin glulisine controls hyperglycemia. Insulin glulisine is applicable to research related to type 1 diabetes and type 2 diabetes.
Insulin Receptor  
Type 1 Diabetes  
/
HY-108743 Insulin degludec
Insulin degludec is an ultra-long-acting form of insulin used for the research of hyperglycemia caused by type 1 and type 2 dabetes. Insulin degludec shows binding efficiency with an IC50 value of 19.59 nM for insulin receptor. Insulin degludec can be used for the research of type 1 and type 2 diabetes.
Insulin Receptor  
Type 1 Diabetes   Type 2 Diabetes  
/
HY-Y0399 L-Norvaline
L-Norvaline is the inhibitor for arginase, that promotes the production of NO, reduces oxidative stress, improves insulin resistance, and exhibits antioxidant and anti-hyperglycemic effects. L-Norvaline can be used in research of Alzheimer’s disease.
Amyloid-β   TNF Receptor   Arginase  
Metabolic or Endocrine Disease   Breast Cancer   Alzheimer's Disease   Lung Fibrosis  
/
HY-113126 3-Hydroxyisobutyric acid
3-Hydroxyisobutyric acid is an intermediate in the metabolic pathways of L-valine and thymine, and can be found in urine. 3-Hydroxyisobutyric acid is a secreted mediator of endothelial cell fatty acid transport and insulin resistance. 3-Hydroxyisobutyric acid can also inhibit key enzymes of energy metabolism in the cerebral cortex of young rats. The levels of 3-Hydroxyisobutyric acid are closely related to various diseases such as 3-hydroxyisobutyric aciduria, diabetes, and ketoacidosis.
Endogenous Metabolite   ATP Synthase  
Neurological, Eye or Ear Disease   Glucose Metabolism  
/
HY-157839 PROTAC α-Synuclein/Tau degrader 1
PROTAC α-Synuclein/Tau degrader 1 is a blood-brain barrier-penetrant dual PROTAC degrader of α-synuclein (α-Syn) and tau, with DC50 of 1.57 μM and 4.09 μM, respectively. PROTAC α-Synuclein/Tau degrader 1 binds to α-Syn and tau PFF, with KDs of 0.47 and 2.78 μM, respectively. PROTAC α-Synuclein/Tau degrader 1 exhibits degradation effect mediated by the ubiquitin-proteasome system (UPS). PROTAC α-Synuclein/Tau degrader 6 can be used for the study of Parkinson’s disease (PD) (Pink: α-Synuclein/Tau ligand (HY-151035); Blue: CRBN ligase ligand (HY-14658); Black: Linker (HY-128803)).
PROTACs   α-synuclein   Tau Protein  
Parkinson's Disease  
/
HY-NP0204 MSA Protein
MSA Protein (Mouse Serum Albumin) is most abundant protein in plasma, which leaks into the brain parenchyma when the blood-brain barrier (BBB) is impaired. Mouse Serum Albumin induces astrocytes to A1 phenotype to remarkably increase levels of Elovl1. Mouse Serum Albumin promotes VLSFAs secretion and causes neuronal lippoapoptosis through endoplasmic reticulum stress response pathway. MSA-activated microglia triggeres remarkable tau phosphorylation at multiple sites (Ser202/Thr205) through NLRP3 inflammasome pathway. Mouse Serum Albumin decreases the spatial learning and memory abilities in mice. Mouse Serum Albumin can be used for the study of neurodegenerative diseases like Alzheimer’s disease (AD) and frontotemporal dementia (FTD).
ELOVL   Apoptosis   NOD-like Receptor (NLR)   Caspase   Tau Protein  
Neurological, Eye or Ear Disease   Inflammation or Immune System Disease  
/
HY-W015229S 3-Indolepropionic acid-d2
3-Indolepropionic acid-d2 is the deuterium labeled 3-Indolepropionic acid. 3-Indolepropionic acid is shown to be a powerful antioxidant and has potential in the treatment for Alzheimer’s disease.
Isotope-Labeled Compounds   Endogenous Metabolite   Reactive Oxygen Species (ROS)  
Neurological, Eye or Ear Disease   Metabolic or Endocrine Disease  
/
HY-P99471 Bepranemab
Bepranemab is a humanized IgG4 monoclonal antibody that binds to the central region of tau protein. Bepranemab inhibits the seeding, aggregation of pathological tau protein and the spread of tau pathology to distal brain regions. Bepranemab is applicable to research related to Alzheimer's disease.

Species: Human

Tau Protein  
Alzheimer's Disease  
/
HY-138669 C004019
C004019 is a BBB-penetrable and small-molecule PROTAC that targets tau. C004019 can simultaneously recruit tau and E3 ligase, and effectively clear tau proteins by promoting the ubiquitination and proteasome-dependent degradation of tau, thereby improving synaptic and cognitive functions in Alzheimer's disease (AD) mice. C004019 can be used in the research of AD and tau protein-related diseases.
PROTACs   Tau Protein  
Alzheimer's Disease  
/
HY-P991049 Atrosimab
Atrosimab is an Fv-Fc1K fusion protein with an EC50 value of 0.37 nM against humans. Atrosimab inhibits TNF-induced TNFR1 activation, release of IL-6 and IL-8, and cell death, and alleviates neuroinflammation. Atrosimab is applicable to research related to inflammatory diseases, neurodegenerative diseases, acute and chronic inflammation, experimental arthritis, non-alcoholic steatohepatitis, and experimental autoimmune encephalomyelitis.

Species: Human

TNF Receptor  
Experimental Autoimmune Encephalomyelitis   Experimental Autoimmune Encephalomyelitis   Fatty Liver Disease  
/
HY-134850 QC-01–175
QC-01-175 is a Tau PROTAC degrader, with Kd values of 1.2 μM, 1.7 μM and 2.5 μM for wild-type, A152T mutant and P301L mutant tau-441 proteins, respectively. QC-01-175 binds to both Tau and CRBN, triggering ubiquitination and proteasomal degradation of Tau. QC-01-175 preferentially targets disease-associated Tau proteins in frontotemporal dementia. QC-01-175 inhibits MAO activity, with an IC50 of 8.56 μM. QC-01-175 suppresses the elevation of ROS levels. QC-01-175 can be used in studies related to frontotemporal dementia and amyotrophic lateral sclerosis.
PROTACs   Tau Protein   Monoamine Oxidase   Reactive Oxygen Species (ROS)  
Amyotrophic Lateral Sclerosis  
/
HY-130750 Phycocyanobilin
Phycocyanobilin, an orally active antioxidative agent, is an effective scavenger for various reactive oxygen species. Phycocyanobilin can be used for the research of Alzheimer’s disease.

Source: Spirulina platensis

Reactive Oxygen Species (ROS)  
Neurological, Eye or Ear Disease  
/
HY-P990047 Maridebart
Maridebart (AMG133 antibody) is a human immunoglobulin G1-kappa, anti-GIPR (gastric inhibitory polypeptide receptor) monoclonal antibody. Maridebart is the antibody portion of Maridebart cafraglutide (HY-164535) and can be used for the synthesis of antibody-drug conjugates (ADC). Maridebart can be used for the reserrch of obesity and type 2 diabetes .

Species: Human

ADC Antibodies   GLP Receptor  
Type 2 Diabetes   Obesity  
/
HY-59291 Levacetylleucine
Levacetylleucine (N-acetyl-L-leucine), an orally bioavailable and brain-penetrant compound, is an acetylated derivative of amino acid Leucine. Levacetylleucine is the active form of N-acetyl-leucine (NAL). Levacetylleucine attenuates neuronal death and neuroinflammation in the cortical tissue of mice. Levacetylleucine also potentially improves ameliorates lysosomal and metabolic dysfunction. Levacetylleucine improves compensation of postural symptoms after unilateral chemical labyrinthectomy (UL) in rats. Levacetylleucine is promising for research of neurological manifestations of Niemann-Pick disease type C, traumatic brain injury and neurodegeneration prevention.
Amino Acid Derivatives  
Neurodegenerative Disease   CNS Infection   Traumatic Brain Injury  
/
HY-P99022 Gantenerumab
Gantenerumab is a fully humanized anti-Aβ IgG1 monoclonal antibody. Gantenerumab can specifically bind to Aβ fibrils and plaques and can be used in Alzheimer's disease research.

Species: Human

Amyloid-β  
Alzheimer's Disease  
/
HY-P9999 Trontinemab
Trontinemab (RG6102) is a brain-penetrant, anti-amyloid, bispecific and humanizedized IgG1-κ antibody, targeting to Aβ plaques and transferrin receptor 1 (TFR1). Trontinemab binds to fibrillar Aβ as well as Aβ plaques triggering plaque clearance by engaging immune cells on Alzheimer disease (AD) brain sections. Trontinemab also shows specific affinity to cynomolgus and human TFR1.

Species: Human

Amyloid-β  
Alzheimer's Disease  
/
HY-P78239 Apolipoprotein E/APOE Protein, Mouse (HEK293, Fc)
Apolipoprotein E/APOE is crucial in lipid transport and participates in the production, transformation and clearance of plasma lipoproteins. It interacts with various particles, including chylomicrons and high-density lipoproteins, and binds to cellular receptors such as LDLR and VLDLR, promoting uptake. Apolipoprotein E/APOE Protein, Mouse (HEK293, Fc) is the recombinant mouse-derived Apolipoprotein E/APOE protein, expressed by HEK293 , with C-hFc labeled tag.

Species: Mouse; Source: HEK293

/
HY-P704412 Apolipoprotein E/APOE2 Protein, Human (HEK293)
Apolipoprotein E (APOE) plays a key role in lipoprotein-mediated lipid transport and is a core component in the production, transformation, and clearance of plasma lipoproteins. As an amphipathic molecule, APOE binds to various lipoprotein particles, including chylomicrons, chylomicron remnants, VLDL, and IDL, favoring HDL. Apolipoprotein E/APOE2 Protein, Human (HEK293) is the recombinant human-derived Apolipoprotein E/APOE2 protein, expressed by HEK293, with tag free.

Species: Human; Source: HEK293

/
HY-P72083 Apolipoprotein E/APOE Protein, Rabbit (His-SUMO)
Apolipoprotein E/APOE is essential for lipid transport between organs and is a key component of lipoproteins such as chylomicrons and high-density lipoprotein. It binds to cell receptors such as LDLR and VLDLR to promote lipoprotein uptake, and has heparin-binding activity to interact with cell surface proteoglycans. Apolipoprotein E/APOE Protein, Rabbit (His-SUMO) is the recombinant Rabbit-derived Apolipoprotein E/APOE protein, expressed by E. coli , with N-10*His, N-SUMO labeled tag.

Species: Rabbit; Source: E. coli

/
HY-P706233 Amyloid Precursor/APP-770 Protein, Mouse (His)
Amyloid Precursor/APP-770 Protein, Mouse (His) is the recombinant mouse-derived Amyloid Precursor/APP-770 protein, expressed by HEK293, with C-His labeled tag.

Species: Mouse; Source: E. coli

/
HY-P706262 ¹⁵N-Labeled Amyloid Precursor/Beta-APP40 Protein, Human
This protein is prone to aggregation after reconstitution, immediate use and smaller package sizes are recommended.

Species: Human; Source: E. coli

Isotope-Labeled Recombinant Proteins

/
HY-P706263 ¹³C, ¹⁵N-Labeled Amyloid Precursor/Beta-APP40 Protein, Human
This protein is prone to aggregation after reconstitution, immediate use and smaller package sizes are recommended.

Species: Human; Source: E. coli

Isotope-Labeled Recombinant Proteins

/
HY-P706264 ¹⁵N-Labeled Amyloid Precursor/Beta-APP42 Protein, Human
This protein is prone to aggregation after reconstitution, immediate use and smaller package sizes are recommended.

Species: Human; Source: E. coli

Isotope-Labeled Recombinant Proteins

/
HY-P706265 ¹³C, ¹⁵N-Labeled Amyloid Precursor/Beta-APP42 Protein, Human
This protein is prone to aggregation after reconstitution, immediate use and smaller package sizes are recommended.

Species: Human; Source: E. coli

Isotope-Labeled Recombinant Proteins

/
HY-P83754 beta Amyloid 1-42 Antibody (YA3555)
beta Amyloid 1-42 Antibody (YA3555) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to beta Amyloid 1-42.

Host: Rabbit; Reactivity: Human, Mouse

Monoclonal Antibodies Recombinant Antibodies Primary Antibodies

/
HY-P83753 beta Amyloid 1-40 Antibody (YA3554)
beta Amyloid 1-40 Antibody (YA3554) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to beta Amyloid 1-40.

Host: Rabbit; Reactivity: Human, Mouse

Monoclonal Antibodies Recombinant Antibodies Primary Antibodies

/
HY-P86422 beta-Amyloid Antibody (YA6114)
beta-Amyloid Antibody (YA6114) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to beta-Amyloid.

Host: Rabbit; Reactivity: Human, Mouse, Rat

Monoclonal Antibodies Recombinant Antibodies Primary Antibodies

/
HY-P86747 beta-Amyloid 1-42 Antibody (YA6439)
beta-Amyloid(1-42) Antibody (YA6439) is a Mouse-derived and non-conjugated IgG2b monoclonal antibody, targeting to beta-Amyloid(1-42).

Host: Mouse; Reactivity: Human

Monoclonal Antibodies Primary Antibodies

/
HY-P83755 beta Amyloid Antibody (YA3556)
beta Amyloid Antibody (YA3556) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to beta Amyloid.

Host: Rabbit; Reactivity: Human, Mouse

Monoclonal Antibodies Recombinant Antibodies Primary Antibodies

/
HY-P81385 Amyloid Precursor Protein Antibody (YA1130)
Amyloid Precursor Protein Antibody (YA1130) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Amyloid Precursor Protein.

Host: Rabbit; Reactivity: Human

Monoclonal Antibodies Recombinant Antibodies Primary Antibodies

/
HY-P81385A Amyloid Precursor Protein Antibody (YA1130)(PBS only)
Amyloid Precursor Protein Antibody (YA1130) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Amyloid Precursor Protein.

Host: Rabbit; Reactivity: Human

Monoclonal Antibodies Recombinant Antibodies Primary Antibodies

/
HY-P82823A Phospho-Amyloid Precursor Protein (Thr743) Antibody (YA2568)(PBS only)
Phospho-Amyloid Precursor Protein (Thr743) Antibody (YA2568) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Phospho-Amyloid Precursor Protein (Thr743).

Host: Rabbit; Reactivity: Human, Rat

Monoclonal Antibodies Recombinant Antibodies Modification Specific Antibodies Primary Antibodies

/
HY-P86747A beta-Amyloid 1-42 Antibody (YA6439)(PBS only)
beta-Amyloid(1-42) Antibody (YA6439) is a Mouse-derived and non-conjugated IgG2b monoclonal antibody, targeting to beta-Amyloid(1-42).

Host: Mouse; Reactivity: Human

Monoclonal Antibodies Primary Antibodies

/
HY-P82823 Phospho-Amyloid Precursor Protein (Thr743) Antibody (YA2568)
Phospho-Amyloid Precursor Protein (Thr743) Antibody (YA2568) is a Rabbit-derived and non-conjugated IgG monoclonal antibody, targeting to Phospho-Amyloid Precursor Protein (Thr743).

Host: Rabbit; Reactivity: Human, Rat

Monoclonal Antibodies Recombinant Antibodies Modification Specific Antibodies Primary Antibodies

/

Keywords

SGLT2 inhibitors | cognitive impairment | dementia | Alzheimer disease | type 2 diabetes | dapagliflozin | empagliflozin | neuroinflammation | cerebral metabolism | drug repurposing